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Abstract 
Background: Obesity, in addition to being a serious condition in its own right, is causally 
associated  with  many  chronic  non-communicable  diseases,  and  its  prevention, 
identification and treatment is a public health priority.  
Results: The main findings of the present thesis were that 1) many drugs, used in the 
management of chronic disease, have an adverse effect on body weight with weight change 
of +10kg observed as a real side effect of some.  2) Identification and management of 
obesity  is  not  a  formal  part  of  current  practice  in  many  secondary  care  clinics.  While 
acknowledging the adverse health effects of obesity within their specialist areas, clinicians 
felt  under-skilled  and  insufficiently  resourced  to  provide  effective  management.  3) 
Improvements in iron status in pre-menopausal women can be achieved during weight loss, 
using eating plans that either include or exclude red meat.  The data while in-conclusive 
suggest that a diet including red meat may confer greater benefits on iron status.  
Discussion:  Weight gain is an adverse effect of many drugs used to treat chronic diseases.  
This should be discussed with patients prior to treatment and advice provided on how to 
avoid  or  minimise  weight  gain.    NHS  secondary  care  consultants  are  concerned  about 
obesity and its impact on their patient’s health.  Most have no weight management strategy 
and would like one.  This will require additional training and resources. Excluding red 
meat did not adversely affect iron status in pre-menopausal women.  A larger study is 
required for definitive health promotion advice.   
Conclusion: Pharmacotherapy is a significant factor in the rising prevalence of obesity. 
Weight management is not an integral part of patient care in secondary care clinic settings.  
The exclusion of red meat during weight management does not compromise iron status in 
pre-menopausal women with low iron stores. 
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Summary 
Chronic non-communicable diseases are now a significant cause of disability and death.  
Obesity, in addition to being a serious condition in its own right, is causally associated 
with many non-communicable diseases and its prevention and treatment is now a public 
health priority.  As the development of obesity is a multi-factorial process, prevention and 
management will require multifaceted interventions which address the many contributory 
factors.   
 
The aims of the present thesis were: 
1) To determine the effect that “obesogenic” drugs have as an adverse effect on body 
weight. 
2) To determine the current practices in relation to weight management currently provided 
for  overweight/obese  patients  attending  different  secondary  care  outpatient  clinics  in 
Scotland. 
3)  To  determine  the  effect  of  a  programme  for  weight  loss  and  maintenance,  which 
included the regular consumption of red meat in comparison to one that excluded it, on 
iron status in young women, recruited from work-sites. 
 
In order to achieve these aims in 3 separate studies, a range of techniques used in Human 
Nutrition research were employed.  A postal questionnaire survey, a systematic review and 
randomised controlled study were carried out.  This PhD training was thus able to include 
aspects of the aetiology of obesity and of its management with an assessment of practice in 
relation to current guidelines and so contribute to this evidence base.   xii
Aetiology of obesity: obesogenic drugs 
Several drugs, or categories of drugs, listed by the WHO and other writers, and used in the 
treatment of chronic disease, are consistently associated with weight gain as a side effect 
and considered “obesogenic”.  However the extent to which they may contribute to the 
multi-factorial process behind obesity is not well documented.  
An electronic search of Medline 1966-2004, Embase 1980-2004, PsycINFO 1967-2004, 
and the Cochrane Register of Controlled trials identified 43 randomised controlled trials 
that fulfilled the inclusion criteria for this systematic review.  In the majority of studies the 
main  objective  was  to  compare  the  efficacy  and  safety  of  drug  therapy  for  a  separate 
endpoint, but with weight change recorded under safety outcomes.  Weight change was a 
primary outcome measure in only 6 studies.  There was evidence of weight gain for all the 
drugs included, up to 10kg at 52 weeks.   
 
The review provides evidence of the weight gain potential of some common drugs.  It is 
perhaps only now, in light of the present epidemic of obesity, that this undesirable effect 
on body weight has become a highly pertinent issue.  Weight change up to a mean +10kg 
has been observed in good quality controlled trials as a real side effect of some drugs.  
Data on body weight are often not recorded in published clinical trials or is reported in 
insufficient  detail.    This  side  effect  has  potentially  serious  consequences,  should  be 
mentioned  to  patients,  and  weight  management  measures  routinely  considered  when 
prescribing  drugs  known  to  promote  weight  gain.    Future  clinical  trials  should  always 
document weight changes.   xiii
Attitudes,  beliefs  and  current  practice  in  secondary  care  for  weight 
management 
One  hundred  consultant  clinicians  were  surveyed,  using  a  postal  questionnaire,  to 
determine  current  practices  with  regard  to  the  identification  of  and  management  of 
overweight /obesity in patients attending different secondary care outpatient clinics.   
The overall response rate was 55%.  However, only 9% (5) of clinicians reported having a 
protocol in place for the management of patients who were overweight or obese.  Lack of 
expertise and inaccessibility to expertise were cited frequently as reasons for having no 
protocol  in  place.    Fifty  one  percent  felt  that  weight  management  (including  obesity 
treatment) should be undertaken by a specialist service either run by general practitioners 
(GP), or by clinicians in a secondary care setting.  Around one-third of all those surveyed 
reported  a  willingness  to  incorporate  obesity  management  within  their  own  routine 
specialty practice. 
 
Clinicians  acknowledged  that  there  were  adverse  health  effects  of  obesity  within  their 
specialist  areas,  but  felt  under-skilled  and  insufficiently  resourced  to  provide  effective 
management.  Effective prevention and management are required to challenge the obesity 
epidemic  and  will  require  the  involvement  of  both  primary  and  secondary  care  NHS 
settings.  It was encouraging that a third of respondents felt prepared to incorporate obesity 
and weight management within their routine specialist practice. 
 
Replacing Myth with evidence in weight management: Avoiding Meat 
Iron deficiency is major global public health problem and common in the UK especially in 
pre-menopausal women.  Habitual dieting can deplete iron stores especially if intake of 
haem-iron is restricted but also iron rich bread and cereal foods are restricted.  Women 
often specifically exclude red meat while slimming, which has potential implications for 
iron status.  Their avoidance of meat does not emerge from evidence based advice and   xiv
seems to have arisen from myth.  A randomised clinical study was designed to evaluate the 
effect of a weight loss diet that included the regular consumption of red meat, compared 
with a diet that excluded red meat.  Thirty six overweight, pre-menopausal women, with a 
mean serum ferritin 15.8 (SD 3.1) ug/l (normal range 10.0-275.) entered the study.  Dietary 
advice was delivered using a one-to-one approach with review every two weeks.  
 
Thirty women completed the study.  Weight change at week 12  was -2.8 (SD1.9) kg, 
p<0.0001 (meat), -2.6 (SD 2.4) kg, p<0.0001 (no meat).  Serum ferritin improved in both 
diet groups at wk 24, with no significant difference between the groups.  This increase was 
significant for the groups combined +3.24 (SD 9.02) ug/l (p=0.03).  This increase will have 
represented regression to the mean, as subjects were recruited on the basis of low ferritin.  
There was some suggestion (p =0.07) that in women consuming meat, better adherence to 
dietary advice, with greater weight loss, led to greater improvements in serum ferritin.  
However observing p<0.05 as the unit of significance, this study concluded that excluding 
red meat did not adversely affect iron status over 24 weeks, conversely, including meat did 
not impede weight loss.  Serum ferritin improved in both diet groups and was the result of 
all participants consuming a diet that was rich in sources of both haem and non-haem iron.  
The data, although inconclusive, suggest better iron status with regular consumption of red 
meat.  A larger study with greater weight loss is required for definitive health promotion 
advice to women with low ferritin.  Including red meat should be an option in any weight 
management programme.  It provides a variety of other nutrients as well as haem-iron. 
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Chapter 1 
Introduction 
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1.1   Obesity and Non-communicable diseases 
Diet and lifestyle are acknowledged to be important factors in the maintenance of health 
and the prevention of disease.  Over the last few decades the lifestyle and diets of many 
populations has changed significantly, with diets becoming richer in high-fat, high-energy 
foods, while lifestyles have become more sedentary.  A consequence of these changes is 
that  chronic  non-communicable  diseases  related  to  overweight  and  obesity  including 
diabetes mellitus, cardiovascular disease (CVD), hypertension and stroke, and some types 
of cancer, are increasingly significant causes of disability and premature death (Table 1.1) 
the need to promote healthier diets and lifestyles to prevent chronic disease has long been 
advocated  (WHO  2003),  but  obesity  rates  are  climbing  rapidly  in  most  post-industrial 
countries 
 
1.1.1 Diabetes 
In  addition  to  being  a  serious  condition  in  its  own  right  obesity,  and/or  the  diet  and 
lifestyles that promote it, is associated with many of the other non-communicable diseases 
and most spectacularly with type 2 diabetes.  Increases in obesity over the past 30 years 
have been paralleled by a dramatic rise in the prevalence of diabetes.  Over this time-frame 
the  incidence  of  type  2  diabetes  in  the  US  is  reported  as  doubling  with  much  of  the 
increase observed among people with a BMI > 30 kg/m
2 (Fox et al., 2003).  Diabetes risk 
increases as soon as BMI rises above 23kg/m
2 and Relative Risks approach 100 with BMI 
>35 kg/m
2 (Carey  et al., 1997).   As people become more overweight at  younger  ages 
(www.heartstats.org, SHS 2003, www.diabetes.co.uk) so type 2 diabetes and its vascular 
complications will emerge at younger ages and total prevalence increases.   It is anticipated 
that type 2 diabetes will become one of the major public health issues of this century 
(Williams, 1999).     3 
1.1.2 Cancer 
There is less, but rapidly increasing, recognition that increased body weight can lead to the 
development of cancer. (McMillan et al., 2007, World Cancer Research Fund, 2006).  The 
evidence  that  body  fatness  is  a  cause  of  certain  cancers  is  reported  as  convincing  for 
cancers  of:  -  oesophagus,  pancreas,  colon  and  rectum,  postmenopausal  breast  cancer, 
endometrium and kidney.  Maintaining a healthy body weight is recommended as “one of 
the most important ways to protect against cancer” (World Cancer Research Fund 2006).  
In the US it is estimated that obesity could account for 14% of cancer deaths in men and 
20% in women (Calle et al., 2003).  UK data show that increasing BMI is significantly 
associated with increased risk of developing cancer and in post-menopausal women 5% of 
cancers  can  be  attributed  to  obesity  (Reeves  et  al.,  2007),  -  i.e.  they  would  not  have 
occurred without obesity.  UK data for both men and women estimate that 4% of all cases 
of  cancer  could  be  avoided  if  BMI’s  exceeding  25kg/m
2  could  be  avoided  (Cancer 
Research UK 2006).  The differences between UK and US data may reflect the differing 
prevalence  of  obesity,  the  US  having  a  higher  rate  than  the  UK  (Centres  for  Disease 
Control  and  Prevention  2008,  British  Heart  Foundation  2006).    However  as  obesity 
prevalence  continues  to  rise  in  the  UK  it is  likely  that  the  percentage  of  cancer  cases 
attributable to obesity will increase also. 
 
1.1.3 Hypertension 
The association between overweight/obesity and hypertension is well recognised (Garrison 
et  al.,  1987,  WHO,  1998).    Indeed  excess  weight  is  considered  one  of  the  strongest 
predictors of hypertension with the incidence more frequent in obese people in comparison 
to lean counterparts (Poirier et al., 2006).  More recent research suggests that increased 
visceral fat accumulation, with large waist circumference, is the best marker and predictor 
of hypertension rather than obesity without central fat distribution (Iacobellis & Sharma, 
2006).    Moderate  weight  loss  has  a  beneficial  effect  on  cardiovascular  risk  factors   4 
including hypertension, with the greatest benefits seen soon after weight loss (Aucott et al., 
2005).  There may be permanent effects of prolonged obesity on blood pressure regulators, 
as after weight loss hypertension recurs when weight has stabilised, even after bariatric 
surgery (Sjostrum et al., 2000).   
 
1.1.4 Stroke 
While  the  relationship  between  obesity  and  CHD  is  well  established  the  association 
between obesity and stroke is more complicated (Hu et al., 2007).  Some studies have 
shown a relationship (Folsom et al., 1990, Rexrode et al., 1997, Kurth et al., 2002) whilst 
others do not (Curb & Marcus, 1991).  High blood pressure is an important causal factor.  
As with hypertension recent research suggests that abdominal adiposity more than BMI is 
associated with an increased risk of stroke in men (Hu et al., 2007, Suk et al., 2003).   
 
1.2   Factors influencing the development of overweight and obesity 
1.2.1 Genetics 
It is well documented that familial factors are important but estimates of heritability vary 
markedly the lowest being 5% and the highest 90% (Loos & Bouchard, 2003).  So-called 
“simple  obesity”  occurs  when  a  person’s  individual  makeup  is  susceptible  to  an 
environment that promotes excess energy consumption over energy expenditure, (Mutch & 
Clement, 2006).  In contrast to the rare identification of single gene mutations that cause 
obesity,  the  identification  of  any  specific  polygenic  profile  associated  with  the 
development of “simple obesity” is proving more elusive (Fisler & Warden, 2007).  It is 
likely to be a complex situation involving several genes that will result in individuals being 
predisposed to obesity but only after prolonged exposure to environmental factors (Hitman, 
1998).  As an example a recent candidate gene to be identified is the FTO (fat mass and 
obesity) gene.  Those with a common variant in this gene are said to be 70% more likely to 
become overweight or obese in comparison to those who do not (Frayling et al., 2007).  It   5 
is not explained how the variant in the FTO gene actually causes this modest increase in 
risk of weight gain.  Many people with this gene do not become obese, so it may contribute 
to risk under some conditions.  It is not sufficient to have the gene to become obese as its 
effect can be overcome.  Moreover as the gene pool has remained essentially stable over 
several  generations  (Marit  &  Martinez,  2006),  the  rapid  increase  in  obesity  cannot  be 
explained by changes in genetic makeup and it is the environment that is exerting the most 
powerful influence. 
 
1.2.2 Energy Intake 
Food  availability  and  food  choice  determine  the  macronutrient  composition  of  the 
consumed  diet  and  will  have  a  significant  influence  on  energy  intake.  This,  alongside 
physical  activity,  is  considered  one  of  the  major  influencing  factors  on  the  increasing 
prevalence of overweight and obesity (WHO, 2003, Keith et al., 2006, Popkin, 2006).  In 
epidemiological  studies  high-fat  energy-dense  diets  are  strongly  associated  with  the 
increase in the prevalence of obesity (WHO, 1998).  It has been observed that in countries 
where obesity is common the percentage of fat in the diet has been high for many years at 
around 40% if energy intake (WHO, 1998).  However there is much debate on the strength, 
and on the causality of the relationship between dietary fat and the rising epidemic of 
obesity.  Dietary fat has a much higher energy density than other macronutrients but a 
lower  satiating  effect.    It  is  argued  that  the  low  satiety  factor  results  in  passive  over-
consumption and hence high fat diets contribute more to the development of obesity than 
low/lower fat diets (Bray & Popkin, 1998, Bray et al., 2004).  Other researchers suggest, 
on the basis of self-reported dietary data, that the percentage energy from fats has fallen 
(Willet & Liebel, 2002).   
 
Since  the  1960’s  the  available  dietary  energy,  measured  in  kilocalories,  has  risen  by 
approximately 450 kcal/d per person (WHO, 2003).  It is agreed that the overall increase in   6 
calorie  intake  is  a  significant  contributory  factor  in  the  obesity  epidemic,  but  there  is 
confusion  over  exactly  what  it  is  doing.    In  fact  only  a  small  excess  (10-20kcal/d)  is 
enough  to  cause  weight  gain,  (i.e.  fat  accumulation)  but  most  of  the  increased  energy 
consumption is to support the higher BMR of a more overweight population.  One element 
of increased energy consumption is larger portion sizes (Shwartz et al., 2006).  Portion 
sizes, offered by retailers and in catering have risen markedly since the 1980’s, mirroring 
the rising prevalence of obesity (Young & Nestle, 2002, Schwartz et al., 2006).  Increases 
are most evident in convenience foods and foods eaten outside the home (Church, 2008).  
Larger portion sizes eaten out-with the home may distort an individual’s perception of 
what is a normal portion size thus leading to larger portion sizes being served within the 
home (Schwartz et al., 2006).  The portion sizes of foods eaten at home (breakfast cereals, 
breads etc) chosen by a sample of young people were found to be significantly greater than 
those chosen by a similar population 20 years previously (Schwartz et al., 2006).   
 
Eating out-with the home has become more popular and in the US the increase in the 
number of per capita restaurants (fast-food and full service) is estimated to have accounted 
for 65% of the rise of the percentage of the population classified as obese (Chou et al., 
2004). .  In the UK expenditure on foods eaten out-with home has increased by 29% over 
the last decade (Cabinet Office., 2008)    accounted for ~12 % of total energy intake in 
2006 (Defra, 2008).  While this perhaps represents a small proportion of total energy intake 
it may, as suggested previously, influence portion sizes of other foods eaten in the home.   
 
The proportion of energy from fat is higher in foods from catering sources (McCrory et al., 
2000,  Prentice  &  Jebb,  2003).    The  contribution  of  “fast  foods”  to  the  increasing 
prevalence of obesity was reviewed as part of the recent World Cancer Research Fund 
publication (WCRF 2006).  Six studies showed that increased consumption of fast foods 
significantly increased the risk of weight gain in adults.  There was also some evidence of   7 
this effect in children.  The authors concluded that “the evidence that fast foods are a cause 
of weight gain, overweight and obesity is strong and consistent”.  This effect is likely to be 
due to excess energy intake (Prentice & Jebb, 2003).  Also noted was that fast foods are 
often available in large portion sizes. 
 
1.2.3 Energy Expenditure/Physical activity 
For most individuals in society today there is a reduced requirement for physical activity in 
both working and domestic life (WHO 2003, Di Pietro et al., 2004).  In the UK we now 
travel 25% less by foot and by bicycle, have more labour saving devices, fewer people are 
involved in physically demanding jobs, we watch more TV and have less participation in 
sport (Foresight, 2007).  The relationship between physical activity and weight gain is 
unclear.    In  many  studies  an  inverse  relationship  between  physical  activity  is  seen,  in 
others the results are inconsistent (Foglehom et al., 2000).  One review concluded that 
there was uncertainty as to whether physical activity can prevent weight gain (Wareham et 
al., 2004).  More recent data from the National Weight Control Registry suggest that high 
physical activity is vital to avoid weight regain (Cattenaci et al., 2008).  Tsofliou et al have 
suggested that, on the basis of earlier work by Mayer, there may be a threshold level of 
physical activity, above which weight gain does not occur.  Below this level appetite is de-
regulated (Tsofliou et al., 2003).  However while the evidence base requires strengthening 
current guidelines for physical activity should be adhered to.   
 
Current guidelines for physical activity advocate 30 minutes on most days of the week, a 
level that is sufficient to reduce the risk of many  chronic diseases (Blair  &  LaMonte, 
2005).    In  Scotland  although  the  proportion  of  men  and  women  meeting  these 
recommendation has increased since 1998, nationally representative survey figures show 
that around 60% of both men and women still do not reach these levels (SHS, 2003).  
While sufficient to prevent chronic disease, this level of activity is, for many, unlikely to   8 
be sufficient to prevent weight gain, and around 45-60 minutes per day is recommended to 
prevent the shift from normal weight to obesity (Saris et al., 2003).  Recent research also 
suggests that physical activity for around 275 minute per week (40 mins/day), alongside 
continued energy reduction, is required to sustain a 10% weight loss (Jakicic et al., 2008)   
 
It  has  been  suggested  that  fitness  can  compensate  for  the  effects  of  obesity  on 
cardiovascular risk (Katzmarzyk et al., 2004, Church et al., 2004).  Other studies report 
that even with high levels of physical activity obesity was still associated with increased 
total  mortality  (Stevens  et  al.,  2004,  Meyer  et  al.,  2002).    More  recent  research 
(Akbartabartoori  et  al.,  2008)  suggested  that  these  conflicting  results  may  be  due  to 
differing populations and methodologies and aimed to clarify the picture using nationally 
representative cross sectional data.  The authors conclude that both physical activity and 
weight loss are important to reduce cardiovascular risk in those who are obese, but the 
results confirmed that high levels of reported physical activity in obese subjects, was not 
enough to outweigh the effects of obesity on cardiovascular risk.   
 
1.2.4 Other Factors – Pharmaceutical Iatrogenisis 
Whilst changes in diet and physical activity are the key factors in terms of underpinning 
the obesity epidemic other factors have been proposed as additional influencing factors, 
which modify the likelihood of, or extent of weight gain (Keith et al., 2006, Bray et al 
2005).  In principle this could be through influences on 1) food choice and intakes or 2) 
absorption/malabsorption or 3) physical activity or 4) any of the biochemical pathways 
which  contribute  to  energy  expenditure  (Kopleman,  2006).    Currently  there  are  many 
prescription  drugs  in  use  that  are  associated  with  weight  gain  and  this  contributes  to 
“pharmaceutical iatrogenisis” (Keith et al., 2006, Kopleman, 2006).  Many of these are 
used in the treatment of chronic non-communicable diseases.   
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One group of drugs with a long association with weight gain is antipsychotics and several 
reviews have examined their effect on body weight (Cheskin et al., 1999, Allison et al., 
2002, Abramoff Ness & Apovian, 2005).  Allison et al., 2001 reports that many individuals 
prescribed  atypical  antipsychotic  drugs  can  gain  more  than  7%  of  their  body  weight.  
Prescription  medications  used  in  the  treatment  of  non-communicable  diseases  such  as 
diabetes, heart disease and hypertension are also associated with weight gain (Leslie et al., 
2007).   
 
Although weight loss is common in some diseases and regain is a feature of effective 
treatment,  for  many  weight  gain  as  a  result  of  drugs  is  an  unwanted  side  effect.    It 
contributes  importantly  to  non-compliance  and  relapse  of  the  disease  being  treated.  
Weight gain was shown to be the key mediator of non-compliance in patients prescribed 
antipsychotic  medication.    Those  who  were  obese  were  twice  as  likely  to  omit  their 
medication  (Weiden  et  al.,  2004).    Weight  gain  is  also  reported  as  factor  in  non-
compliance with drug therapy in individuals with type 2 diabetes (Rubin, 2005). 
 
Recent research has shown that those who are overweight or obese are more likely than 
those  of  “normal”  weight  to  be  prescribed  drugs  associated  with  weight  gain 
(Counterweight,  2005).    Comparison  of  1150  obese  patients  with  1150  age  and  sex 
matched  controls  of  normal  weight  showed  a  higher  percentage  of  the  obese  were 
prescribed  drugs  used  to  treat  chronic  non-  communicable  diseases,  including  those 
considered obesogenic.  This has the potential to trap individuals in a vicious cycle as any 
existing weight problem may be exacerbated by drug therapy. 
 
The use of many of the drugs associated with weight gain has increased significantly over 
the past 30 years (Keith et al., 2006).  However the evidence about the amount to which 
they can contribute to weight gain is not widely promoted.  Many previous reviews of   10 
obesogenic drugs have been carried out, however many focus only on one class of drugs 
(i.e. beta-blockers Sharma et al., 2001, and antipsychotics Allison et al 2000), were not 
carried out following a systematic approach (Abramof Ness & Appovian, 2005) or do not 
quantify the effect on body weight (Cheskin et al., 1999).   
 
1.3   Dietary approaches for weight management 
Obesity develops over time, often decades, therefore the disease process of obesity is the 
process of excess fat accumulation.  Thus the “cure” for obesity, and primary target of 
weight management, is to achieve a stable weight i.e. to block the process of excess fat 
accumulation.  For most overweight people weight loss is also desirable, but this may 
distract from the need to achieve weight stability and the methods may not be the same.  
The  principles  and  targets  of  modern  weight  management  can  be  traced  to  the  SIGN 
Obesity report (1996):- 
1)  Prevent unwanted weight gain 
2)  Achieve weight loss (at least 5-10%) 
3)  Prevent weight gain 
4)  Improve health and risk factors of obese people, whether or not they lose weight 
and prevent further weight gain 
 
There is no one method of weight loss that will suit all (Lean, 1998).  Weight loss can be 
achieved via a wide range of approaches (Klem et al., 1997), and a huge literature of lay 
books  exists  (Which,  2001).    However  many  promote  variable  and  often  ill-advised 
methods including those that involve eliminating or severely restricting the consumption of 
particular groups of food.  One of the most popular approaches over the last decade has 
been the Atkins Diet, which advocates limiting consumption of carbohydrates to less than 
20g/d while allowing unlimited consumption of fats and protein.  In comparison with other 
weight loss approaches, a high protein approach is probably comparable in terms of weight   11 
loss (Dansinger et al., 2005).  However, attrition at one year in the Atkins group was the 
second highest of the four approaches examined at 48%.  This suggests that the Atkins 
approach is more difficult to sustain over the longer term.  Another research study reports 
no difference in weight loss between the Atkins approach and other methods at one year 
but also reports that adherence was poor (Foster et al., 2003).  So although having some 
success for weight loss there would appear to be no great advantage over other methods 
which allow consumption of all food groups.  
 
Limiting specific food groups may have unwanted nutritional effects.  Reducing fat intake, 
in particular saturated fats, has value for both health and weight control.  However advice 
promoted by health professionals to reduce fat intake is interpreted by some as a need to 
reduce or eliminate red meat from their diets (Houston et al., 1997).  In a previous study 
(Leslie et al., 2002), the effect on serum lipids of the inclusion or exclusion of red meat as 
part  of  a  weight  reduction  diet  was  investigated.    Anecdotal  reports  from  participants 
recruited to this study suggested that excluding red meat  was often a  first step during 
slimming.    One  survey  found  that  avoidance  of  red  meat  was  one  of  the  most  highly 
adopted behaviours for reducing fat intake.  Red meat was replaced by fish and poultry 
only some of the time by the majority of survey participants.  Reduced consumption of 
foods  more  likely  to  affect  fat  intake  were  ignored.    Such  dietary  behaviour  also  has 
implications for iron intake (Capps et al., 2002).   
 
Today it is non-haem iron, found in cereal products, which provides most of dietary iron 
(Gregory et al., 1990).  Diets low in carbohydrates may therefore also lead to a lack of iron 
as many of these cereal foods are fortified with iron.  This problem would be aggravated 
by  a low intake of  Vitamin C, which is also common in both slimming diets  and the 
general population of Scotland.  Vitamin C is a known enhancer of iron absorption.  Data   12 
from the Women’s Cohort Study has shown dietary  Vitamin C intake to be positively 
associated with serum ferritin (Cade et al 2005). 
 
Iron  status  is  described  as  “a  continuum  from  iron  deficiency  with  anaemia  to  iron 
deficiency with no anaemia, to normal iron status” (WHO, 2001).  Depletion of iron stores 
is the first stage in the development of iron deficiency and ultimately anaemia.  At an early 
stage the mobilisation of iron from the storage compartment is initiated, serum ferritin 
levels fall but haemoglobin levels remain normal (Fig 1.2).  While iron depletion itself has 
no  adverse  health  consequences  it  represents  an  increased  risk  of  developing  iron 
deficiency, particularly if there is blood loss (Cook et al., 1992, Watts et al 1988).  Iron 
depletion is a common finding- in menstruating women (Duport et al., 2003).  
 
Clinical guidelines for the management of obesity in Scotland published in 1996 (SIGN) 
recommended a 12-week weight loss period using a 600 kcal daily energy deficit (ED) to 
achieve moderate weight loss.  At that time this recommendation was supported only by 
one small non-randomised audit (Frost et al., 1991).  A subsequent RCT that compared the 
ED approach with a standard 1500 kcal approach found that compliance with advice was 
better with the individualised approach (ED) (Leslie et al., 2002), confirming the findings 
of  the  limited  research  already  completed  in  this  area.    Good  compliance  with 
macronutrient prescriptions to reduce fat and especially saturated fat, optimises weight loss 
but may also be more likely to lead to long term changes in dietary habits thus improving 
the likelihood of maintaining weight loss and improving long term health.  The 600 kcal 
individualised ED (Lean & James, 1986) approach advocates a balanced diet based on 
healthy eating advice with no food group restricted or eliminated, and is recommended in 
the recently published NICE guidelines (NICE 2006). 
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Amongst women with poor iron status habitual dieting for weight loss is reported to have a 
negative effect on iron stores (Houston et al., 1997).  In the late 1990’s approximately 38% 
of women in the USA reported trying to lose weight (Kruger, 2004).  In the UK in 2000-
2001 around 24% of women reported trying to lose weight (NDNS, vol 5 2004).  Thus 
between one-third and one half of overweight and obese women are actively “slimming” 
by restricting some components of their diets.  Previous research has shown that many 
women  who  attempt  weight  loss  do  not  consult  health  professionals  but  follow  a  diet 
devised independently (Wardle & Johnstone 2002).  As the prevalence of obesity continues 
to rise, as it has in both countries, so too will the number of people attempting weight loss, 
especially women, who are twice as likely to attempt weight loss than men (NDNS vol 5 
2004).   
 
In the United Kingdom 11% of women were found to have a serum ferritin below 15ug/l, 
and 8% women had a haemoglobin level below 12 g/dl (NDNS 2004,vol 4).  In Scotland 
the prevalence of iron deficiency anaemia, defined by a haemoglobin level <12g/dl, in 
women aged 16-24 was reported at 7.3%, rising to 12.3% in the 35-44 age group
 (SHS 
2003).   
 
No effect on iron status was observed in the study carried out by  Leslie et al (2002). 
However  this  study  was  carried  out  in  a  male  population  who  do  not  show  the  same 
variations in iron status as pre-menopausal women.  The main cause of iron depletion in 
men would largely be due to chronic blood loss, this is in contrast to pre-menopausal 
women who are susceptible to iron deficiency anaemia due to the demands of menstruation 
and  pregnancy  on  their  smaller  iron  stores.    These  study  results  therefore  have  little 
application to females.  The elimination of red meat as part of slimming plans without 
concomitant  dietary  improvements  may  well  deplete  iron  stores  and  contribute  to  iron 
deficiency and anaemia in pre-menopausal women.   14 
 
Given  the  epidemic  of  overweight  and  obesity  and  the  prevalence  of  iron  deficiency, 
research is required to determine the best approach for weight loss, which will preserve 
iron status in pre-menopausal women.   
 
1.4.   Identification of overweight/obesity  
The  identification  of  those  who  are  overweight  or  obese  is  a  crucial  first  step  in  its 
management.  Given the large numbers of overweight and obese subjects, primary care is 
usually identified as the most appropriate setting for weight management both in the UK 
and the US (SIGN 1996, Sciamanna et al., 2000).  There is widespread popular awareness 
of increasing obesity, but little incentive for routine measurement.  A recent UK audit 
found that obesity was  under-recognised in the primary  care setting.   Amongst 40 GP 
practices that had expressed an interest in weight management only two-thirds of patients 
had a weight or BMI recorded in their medical records (Counterweight, 2004).   
 
The recently published NICE guideline for weight management proposes that all sectors of 
the  NHS  should  be  involved  in  the  identification  and  management  of  overweight  and 
obesity. (NICE, 2006).  Many of the non-communicable diseases associated with obesity 
are primarily managed in secondary care settings.  However, as in primary care, it has been 
reported that only a small percentage (<10%) of those who were overweight/obese were 
identified as such in secondary care clinics in the UK (Cleator et al., 2002).  A prospective 
study was then carried out to determine the actual prevalence of obesity amongst those 
attending secondary care clinics.  Between 20-30% of those attending the clinics were 
identified as overweight or obese, a figure reported as below the true prevalence at that 
time.  This situation is not unique to the UK health service as in other European countries a 
similar picture is also evident with obesity being recorded in only a minority of health care 
records. (Hauner et al., 1996).     15 
 
Lack  of  awareness  amongst  physicians  regarding  the  impact  of  obesity  on  disease 
progression  and  severity  it  is  suggested,  may  account  for  the  low  rate  of  obesity 
identification in clinics.  It is also suggested that physicians may feel they do not have the 
skills or resources to deal with obesity management and this is a disincentive to identify 
and treat those who are overweight/obese (Cleator et al., 2002).   
 
The identification or recognition of overweight and obesity is a crucial first step in its 
subsequent  management.    Recent  research  has  shown  that  an  increasing  number  of 
individuals fail to recognise that they themselves are overweight or obese (Johnson et al., 
2008).  This may, in part, be due to the normalisation of overweight in today’s society 
(Johnson  et  al.,  2008,  Foresight,  2007).    However  the  consequence  of  this  is  that  if 
individuals do not recognise, or choose not to recognise, that they are overweight it is 
unlikely they will seek help to lose weight.  Even when individuals do recognise they are 
overweight not all attempt to lose weight (Wardle & Johnson, 2002).  Conversely people 
who are advised to lose weight by a health professional are more likely to do so (Galuska 
et al., 1999).  It is therefore of paramount importance that health professionals raise the 
issue  whenever  possible  and  measure  height  and  weight  both  to  allow  accurate 
determination of body mass index and to identify weight gainers.  Suggested opportunities 
for this within the health service are “registration with a general practice, consultation for 
related conditions (such as type 2 diabetes and cardiovascular disease) and other routine 
health checks” (NICE, 2006). 
 
Previous research has indicated that secondary care clinics, responsible for managing many 
non-communicable  diseases  to  which  obesity  is  a  contributory  factor,  are  an  ideal 
opportunity to identify overweight/obesity and initiate treatment (Cleator et al., 2002).   
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Clinical guidelines, which are systematically developed, are intended to aid and inform the 
decision making process regarding appropriate health care for specific conditions (West & 
Newton, 1997).  Guidelines are now available for a wide range of conditions including 
many of those associated with obesity.  Clinical guidelines for colorectal cancer, cardiac 
rehabilitation, prevention of cardiovascular disease, stable angina (www.sign.ac.uk), type 2 
diabetes,  myocardial  infarction,  hypertension,  (www.nice.org.uk)  all  state  the  need  for 
weight management, and that those who are overweight or obese should be advised to lose 
weight.  However only two, (stable angina, prevention of CVD), state specifically that 
BMI or waist circumference should be evaluated as part of the clinical assessment.  It is 
important that the measurements required to calculate BMI are taken as if they are not it is 
less likely that overweight/obese patients will be identified.  The perceptions of health 
professionals regarding their patients’ weight status is at odds with actual measurements.  
Research has shown that in 25% of cases physicians failed to recognise that their patients 
were  overweight,  particularly  overweight  men.    Male  physicians  were  less  likely  than 
females to recognise that patients were overweight (Caccamese et al., 2002). 
 
Given the associations between obesity and a wide range of non-communicable diseases 
further  investigation  of  current  practice  with  regard  to  weight  management  within 
secondary  care clinics is warranted as  all opportunities should be used to identify and 
initiate management of those who are overweight or obese (NICE 2006, WHO 2004).  
 
The value of work-site settings for health promotion has been recognised
 (Hennrikas et al., 
1996, HEBS, 1996, NICE, 2006).  Work-sites have been described as “being to adults what 
schools are to children” as a significant amount of time is spent there (Goetzel et al., 2008).  
Work-site based interventions have the advantage of reaching large numbers of people at 
little or no cost who may not seek help in other settings (Hennrikus et al., 1996, Glasgow et 
al., 1993, Goetzel, 2008).  Previous research has shown that while significant number of   17 
workers expressed an interest in smoking cessation and weight loss, when the interventions 
were  offered  out-with  the  work-place  uptake  was  only  1%  compared  to  8-12%  when 
offered on site (Erfurt et al., 1990).  In Scotland employers are able to access a range of 
initiatives aimed at improving the health of their workforce.  One initiative is Scotland’s 
Health at Work (SHAW, now known as Healthy Working Lives) which was established in 
1998 and aims to “encourage and support workplaces to make the active promotion of 
good health an integral part of Scottish corporate culture” (Scottish Executive 2005).  The 
workplace setting is one of the 4 major themes of the recent Scottish Executive Health 
Department report Improving Health in Scotland: The Challenge.  Health promotion or 
occupational health personnel are in a position to target obesity and weight management 
and implement strategies to contribute to reducing the prevalence of obesity and associated 
disorders.   
 
1.5   Research Methods Needed for Weight Management 
The  management  of  obesity  incorporates  prevention  as  well  as  treatment  and  requires 
multifaceted  interventions  to  address  the  many  aspects  that  contribute to  its  increasing 
prevalence.  Evidence is needed from research that covers a wide range of methodologies 
(Lean et al., 2008).  This thesis includes a small selection of different research methods 
applicable  to  obesity  research  including  aspects  of  research  into  both  aetiology  and 
management.   
 
Aetiology 
Obesity, a serious condition in its own right, is associated with many non-communicable 
diseases, which are now a major cause of death and disability.  Many drugs used to treat 
chronic  non-communicable  diseases  are  associated  with  weight  gain  and  considered 
obesogenic.  Pharmaceutical iatrogenisis has been highlighted as a contributory factor in   18 
the aetiology of obesity (Keith et al., 2006, Kopleman, 2006),  however it remains unclear 
to what extent these drugs contribute to weight gain and the development of obesity. 
 
Management 
Many  of  the  non-communicable  diseases  associated  with  obesity,  and  for  which  drugs 
considered  obesogenic  are  prescribed,  are  managed  within  secondary  care  settings. 
Consultations for obesity related conditions are a suggested opportunity to identify and 
initiate management of obesity (NICE 2006).  Previous research in this area found little in 
the way of identification or management of obesity (Cleator et al., 2002) and it remains 
unclear if or how obesity is being managed in secondary care settings.  Given the present 
epidemic of obesity further research is required to ascertain current practice with regard to 
obesity management in this setting. 
Many dietary approaches exist for those who are identified as overweight or obese and 
who wish to lose weight.  However any dietary approach for weight loss should not be 
detrimental to health, give rise to, or exacerbate nutritional deficiencies.  Iron deficiency is 
one of the most common nutritional deficiencies in the UK among premenopausal women 
(Cabinet  Office.,  2008).    As  women  are  more  likely  than  men  to  attempt  weight  loss 
perhaps repeatedly (NDNS vol 5 2004), research to determine the best approach for weight 
loss while maintaining iron status is important. 
 
1.6  Aims of thesis 
1) To determine the effect that “obesogenic” drugs have as an adverse effect on body 
weight.   19 
2) To determine the current practices in relation to weight management currently provided 
for  overweight/obese  patients  attending  different  secondary  care  outpatient  clinics  in 
Scotland. 
3) To determine the effect on iron status in young women, recruited from work-sites, of a 
programme for weight loss and maintenance, which included the regular consumption of 
red meat in comparison to one that excluded it. 
 
These objective are not closely related, but offered a portfolio of research methodologies 
appropriate to research training in obesity and weight management.  
 
1.6.1 Research questions 
RQ1  Is weight gain an adverse effect of some commonly prescribed drugs? 
RQ2  Is the effect on body weight reported and quantified in studies examining these 
drugs? 
RQ3  Are formal protocols to routinely identify and manage overweight/obese patients in 
place in secondary care clinics? 
RQ4   Is height and weight routinely measured in secondary care clinics? 
RQ5  What steps are taken to manage patients who are identified as overweight or obese? 
RQ6  Does a weight reduction diet, that regularly includes lean red meat, maintain iron 
status in pre-menopausal women? 
RQ7  Does a weight reduction diet, which excludes lean red meat, maintain iron status in 
pre-menopausal women? 
RQ8  Do the effects on iron status differ between treatments?   20 
 
 
Table 1.1 Medical Consequences of Obesity (Lean et al 2002) 
Tiredness/Depression  Diabetes  Cancers 
Stroke  Non-alcoholic  fatty  liver 
disease 
Osteoarthritis 
Idiopathic Intracranial  
Hypertension 
Dyslipidaemia  Phlebitis 
Cataracts  Gall bladder disease  Skin disorders 
Pulmonary Disease  Hypertension  Gout 
Coronary Heart Disease  Back pain   
Pancreatitis  Gynaecological 
abnormalities 
 
.   21 
Figure  1.2  Stages  in  the  development  of  iron  deficiency.  IDE,  iron-deficient 
erythropoiesis; IDA, iron-deficient anaemia; SF, serum ferritin; TfR, transferrin receptor. 
(Fairweather Tait 2004 Adapted from Suominen et al. 1998.)
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Chapter 2 
Methods   23 
2.1   Study  1:  Weight  gain  as  an  adverse  effect  of  some 
commonly prescribed drugs: a systematic review 
 
2.1.1 Systematic Reviews 
The number of scientific papers published annually is extensive (Mulrow 1994) and for 
most researchers or health professionals review of all published papers on any given topic 
would be time consuming and unfeasible.  A systematic literature review brings together 
large  amounts  of  information  and  provides  information  about  the  effectiveness  of 
interventions by identifying, appraising and summarising large quantities of research.   
Well defined inclusion criteria and critical appraisal of studies allows unsound studies to 
be excluded and thus a systematic review presents only studies carried out using robust and 
reproducible methods (Greenhalgh, 1997).  Systematic reviews are replicable, scientific 
and transparent and by following explicit methods, minimise bias.  Detailed guidelines on 
how  to  conduct  a  systematic  review  are  available 
http://www.york.ac.uk/inst/crd/index.htm. 
The most obvious and accessible sources of data for a systematic review are electronic 
databases such as Medline.  However even the most rigorous database search may miss 
relevant papers.  Thus other sources should also be used and these include: reference lists 
of published papers, “grey literature”, unpublished sources, and raw data from published 
trials (Greenhalgh, 1997, NHS Centre for Reviews and Dissemination 2001). 
 
2.1.2 Selection of Studies 
For  the  present  study  an  electronic  search  of  Medline  1966-2004,  Embase  1980-2004, 
PsycINFO 1967-2004, and the Cochrane Register of Controlled trials was performed.  The 
drug name or drug category was the primary key word for each search i.e.:- 
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Antidepressive agents, Tricyclic/ae [Adverse effect] 
(weight  adj2  gain).mp  [mp=  title,abstract,cas  registry/ec  number  word,  mesh  subject 
heading] 
Combine 1 AND 2 
Limit  to  (human  and  English  language  and  all  adult  <19  plus  years  and  clinical  trial, 
randomised controlled trial, controlled clinical trial 
 
Reference  lists  of  all  relevant  papers  were  checked.    Hand-searching  of  journals  or 
searches of grey literature were not undertaken as part of this review due to time and 
resource constraints.   
 
Articles were selected on the basis of title and abstract.  Studies were included according to 
the following eligibility criteria: only randomised controlled studies were included, adult 
participants  (>18  yrs)  prescribed  a  drug  considered  obesogenic,  duration  of  at  least  3 
months and compared the “obesogenic” drug with placebo, an alternative drug or other 
treatment.  Outcome measures had to include measured weight change, which was reported 
quantitatively.    Studies  that  primarily  investigated  the  use/effect  of  a  combination  of 
“obesogenic”  drugs  were  excluded,  as  were  studies  in  which  body  weight  was  self-
reported.  For each drug those used to treat diseases characterised by weight loss (e.g. Type 
1 diabetes) were also excluded.   
Reference Manager Version 11 (The Thomson Corporation) was used to sort and manage 
all data. 
 
2.1.3 Quality Assessment 
Two reviewers checked independently that the studies identified by the search strategy met 
the  inclusion  criteria  and  assessed  the  methodological  quality  of  the  included  studies.  
Quality assessment focussed on the adequacy of the randomisation procedure and followed   25 
the guidelines outlined in the University of York’s guide to undertaking systematic reviews 
(NHS Centre for Reviews and Dissemination 2001). 
 
As the identified studies involved different populations, drugs and dosages no quantitative 
meta-analyses were performed. 
 
2.2  Study 2: Weight management: a survey of current practice 
in secondary NHS settings in 2004 
 
2.2.1 Postal Questionnaires 
This  was  a  postal  questionnaire  survey.    The  questionnaire  used  (Appendix  1)  was 
developed by the author and peer reviewed by both supervisors.  Prior to the main survey 
the questionnaire was piloted, by post, with a convenience sample of 9 clinicians from 
various clinical specialties, mainly to determine acceptability and clarity.   Three clinicians 
included in the pilot had an interest in obesity management  
 
Postal questionnaires are widely used in health research.  Advantages include low cost and 
ability to collect data from a wide area.  However, a major limitation is commonly a large 
proportion of non-responses.  Previous research has recommended various strategies to 
maximise response rates.  These include: keeping questionnaires short, use of first class 
post, provision of a stamped addressed reply envelope, providing non-respondents with a 
second copy of the questionnaire.  Questionnaires on topics likely to be of interest and 
those originating from university also increased response rates (Edwards et al., 2002).  All 
these strategies were employed in this study. 
 
Validity and reliability are important factors in questionnaire surveys and where possible it 
is preferable to use a previously validated questionnaire.  It was not possible to find such a   26 
questionnaire  for  use  in  the  present  survey.    One  aspect  of  validity  is  concerned  with 
whether a questionnaire will collect the information that is required accurately – that is will 
it do what it is meant to do (face validity).  Piloting gives some indication of face validity 
but does not ensure it.  Content validity is concerned with the extent that the questionnaire 
covers all aspects of the topic under investigation.  Literature review and inclusion of the 
views of experts in the area to be investigated should give a good view of the issues to be 
addressed  (Earl-Slater  2002).    A  test  of  a  questionnaire’s  reliability  is  that  it  yields 
consistent results over time.  The questionnaire survey was not the sole focus of the present 
thesis and therefore detailed techniques to ensure validity and reliability were not pursued.   
It  is  also  noted  that  responses  to  questionnaires  that  investigate  the  management  of  a 
particular condition may differ considerably from practice (Adams et al., 1999). 
 
2.2.2 Participants 
Three health boards adjacent to, but out-with, Greater Glasgow were chosen.  At the time 
of this study there was a great deal of activity within the Greater Glasgow Health Board 
area with regards to obesity management.  A specialist obesity service was about to be 
piloted and a weight management programme was being trialled in primary care.  It was 
felt that this could influence responses with regard to current practice and hence alternative 
health board areas were chosen.  The hospitals chosen within each health board area were 
District  General  hospitals  serving  fairly  large  populations  of  between  78,000-230,000 
people (www.scotland.gov.uk). 
 
2.2.3 Statistical Analysis 
Data management and analysis was carried out using SPSS for Windows (Version 11.5).  
Analysis was mainly descriptive.   
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2.3  Study 3: Influence of red meat consumption on iron status 
in dieting pre-menopausal women. 
 
2.3.1 Study Design 
 
The  study  followed  a  randomised  controlled  design.    Volunteers  attended  for  baseline 
assessment of height and weight to determine BMI, and for blood sampling to determine 
iron status.  Those with a BMI greater than 25 kg/m
2 and a serum ferritin between 10 and 
15ug/l inclusive, were randomised to either include or exclude red meat as part of their 
weight  management  programme.    A  blinded  envelope  system  was  used  for  treatment 
allocation.  Randomisation was stratified by BMI category, (25.1-29.9, 30-34.9 and > 35 
kg/m
2).  The randomisation sequence was produced by the study statistician, (HG), and the 
envelopes prepared by the principal investigator (CH) neither of whom played any part in 
recruitment, treatment allocation or delivery of the intervention.   
 
2.3.2 Subjects/Recruitment 
Subjects were recruited from several worksites located in West Central Scotland between 
April  2005  and  June  2006.    Recruitment  was  carried  out  using  poster  advertisement 
(Appendix 2), posted in staff areas such as canteens and female changing rooms.  The 
posters outlined the study and gave details of when the study researcher would visit the 
work-site for recruitment.  All subjects gave informed consent before entry into the study.  
Ethical Approval was obtained from the West Ethics Committee (Appendix 3). 
 
2.3.3 Exclusion Criteria 
Body mass index below 25 kg/m
2, those who had chosen to exclude meat permanently 
from their diet, post-menopausal, pregnant or less than 6 months post partum, any chronic 
inflammatory disease, iron replete subjects, insulin treated diabetics, any other condition   28 
requiring prescribed food products or specialist dietary intervention, haemoglobin level 
<10 g/dl, serum ferritin < 10 ug/l or >15ug/l.   
The normal range for serum ferritin is 10 to 275ug/l.  The effects of diet on serum ferritin 
were considered more likely in women with serum ferritin levels at the lower end of the 
normal  range  (Dr  C  Tait,  Consultant  Haematologist,  personal  communication).    Power 
calculations for the present study used data from a previous published study (Patterson et 
al.,  2001)  this study  also  used  15ug/l  as  the  upper  limit  for  inclusion.   The  exclusion 
criteria of ferritin <10ug/lwas imposed by the Ethics Committee. 
 
2.3.4 Anthropometric Measurements 
Height  
Height  was  measured  to  the  nearest  mm,  with  the  Frankfort  plane  horizontal,  using  a 
portable  stadiometer  (Chasmors  Ltd,  London).    Body  weight  was  measured  using 
calibrated scales (SECA, Germany) to the nearest 100g in light clothing without shoes.  All 
equipment was new and had been calibrated by the manufacturer. 
 
Waist Circumference 
Waist circumference was measured midway between the lowest rib margin and the lateral 
iliac crest, using a flexible steel tape and ensuring the skin was not compressed. (Holtain 
Ltd, Crymch, UK).  This measurement was made twice and the mean used for analysis. 
 
2.3.5 Assessment of Iron Status 
The assessment of iron status can be made using a range of measurements that include 
haemoglobin (Hb), serum iron, ferritin, transferrin and transferrin receptor.  Serum ferritin 
concentration is the most applicable, least invasive indicator of iron stores (Baynes, 1988, 
Goddart  et  al.,  2005).   It  “provides  a  precise  quantitative  measure  of  total  iron  in  the   29 
storage compartment” (Cooke et al., 1992) and is recommended for the diagnosis of iron 
deficiency  (Ross,  2002).    It  is  also  considered  the  “best  indicator  of  a  response  to  an 
intervention” (WHO, 2004).  However serum apoferritin is an acute phase reactant protein 
and should be used in the absence of infection or inflammation.  Serum ferritin levels less 
than 15 ug/l are indicative of depleted iron stores in both men and women (WHO, 2001).  
This level of serum ferritin has been reported as 75% sensitive and 98% specific for iron 
deficiency (Ross, 2002).   
 
2.3.6 Haematological Measurements 
Venesection was performed to collect samples for full blood count analysis. Participant’s 
reticulocyte count was also examined at baseline to exclude excessive blood loss as a cause 
for any potential iron deficiency.  All samples were analysed by the Dept of Pathological 
Biochemistry at Glasgow Royal Infirmary using standard protocols.   
Ferritin was measured on an Abbot Architect i2000.  Reticulocyte count and haemoglobin 
were measured on a Sysmex XE 2100.  Tests were analysed on an ad hoc basis and not in 
batches.  At the time of the study (2005-2006) the inter assay coefficient of variance for 
ferritin  was  ~7.2%,  ~1.2%  for  haemoglobin  and  ~21%  for  reticulocyte  count  (David 
Cameron,  Haematology  Laboratory  Manager,  Glasgow  Royal  Infirmary,  personal 
communication). 
 
2.3.7 Prediction Equations for Basal Metabolic Rate 
The  equations  most  commonly  used  in  healthy  subjects  in  the  UK  are  the  Schofield 
equations  (Schofield  et  al.,  1985).    Twelve  equations  by  gender  and  age  have  been 
developed to allow the calculation of basal metabolic rate (BMR) from weight for infants, 
children and adults.  While providing a quick and accessible method of determining energy 
requirements the limitations of the equations must be acknowledged.  The original data on 
which they were based are said to include a disproportionate number of Italian subjects and   30 
their universal applicability has been questioned.  Their accuracy in those with a BMI >30 
kg/m2 has also been questioned (Horgan & Stubbs, 2003).  However in a clinical situation 
they are the quickest and least invasive method of calculation energy requirements.  New 
equations have been developed but an expert consultation concluded that they were not 
robust enough to be adopted and that the Schofield equations and their Standard Error of 
Estimates (SEE) should continue to be used.  (WHO, 2001) 
 
The equations for estimating BMR from body weight used in the dietary study were: 
Women  18-30 years = 0.0621 x actual weight in kg + 2.0357    SEE 0.497 
 
31-60 years = 0.0342 x actual weight in kg + 3.5377    SEE 0.465 
 
2.3.8 Diet Intervention 
The approach to be used for the weight management advice was derived from the SIGN 
guidelines  for  obesity  management
  (SIGN,  1996),  with  individualised  advice  aimed  at 
achieving a daily energy deficit of 600 kcal (Lean & James, 1986).  This approach has 
been widely used in clinical trials for weight management, and has proved more effective 
than a fixed diet prescription of 1200 or 1500 kcal/day (Leslie et al., 2002, Frost et al., 
1991).  It is also recommended in the recent NICE guidelines for weight management 
(NICE, 2006).  
 
For  the  initial  12-week  weight  loss  period  subjects’  received  individualised  energy 
prescriptions.  These were calculated using Schofield equations (Schofield et al., 1985).  
An additional activity factor, 1.3 x BMR, was then applied to calculate the energy required 
to remain weight stable.  As the aim was to induce weight loss, a fixed energy deficit was 
introduced  by  subtracting  600-kcal  from  the  individual’s  estimated  daily  energy 
requirements.   
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Macronutrient composition of the two eating plans in both groups was designed to provide 
greater than 50% energy from carbohydrate, less than 35% energy from total fat and under 
20% from protein (COMA, 1991).  Advice was also given to all subjects to restrict or 
avoid alcohol consumption.  The intervention was delivered by the study researcher (WL) 
who was not blinded to treatment allocation. 
 
Maintenance Period 
The two eating plans (meat vs. no meat) were continued during the 12-week structured 
weight maintenance period.  However dietary advice during the weight maintenance period 
followed a non-prescriptive approach.  Healthy eating advice, as described by the balance 
of good health, was reviewed with all participants.  Participants were advised that there 
could  be  some  increase  in  the  portion  size  of  the  components  of  main  meals.    The 
composition  of  main  meal  was  directed  by  the  plate  model,  a  tool  to  assist  dietary 
education  (Armstrong  &  Lean,  1993).    Two  versions  exist,  a  2-component  model,  for 
meals with rice or pasta meals, and a 3-component model for meals comprising meat/fish, 
vegetables and potatoes.  Both versions ensure that meals provide >50% dietary energy 
from  carbohydrate  and  <35%  energy  from  fat  (MAFF,  1993)  (Appendix  4).    All 
participants  continued  to  attend  for  review  every  2  weeks  throughout  the  maintenance 
period.  
 
2.3.9 Detailed Dietary Advice 
An eating plan employing standardised principles has been devised within the Department 
of  Human  Nutrition  and  used  in  previous  weight  management  studies  (Hankey  et  al., 
1997).  In order to encourage the consumption of a varied diet the plan is based on an 
exchange  system  for  three  groups  of  food  “bread”,  “meat”  and  “fruit”.    The  “bread” 
exchanges comprise foods rich in complex carbohydrates such as bread, cereals, rice, pasta   32 
and potatoes.  The “fruit” exchanges are rich in carbohydrate and will provide the main 
source of simple sugars, although some jam or marmalade is permitted in order to ensure 
the palatability of bread (Appendix 5).  All participants were encouraged to increase their 
consumption towards the dietary compositional targets (COMA, 1991).   
 
The  University  of  Glasgow  eating  plan  allows  the  daily  consumption  of  red  meat.  
Participants’ randomised to include red meat were advised to consume this at least five 
times per week in the form of quality lean cuts.  Prior to the commencement of this study 
the eating plan was revised to provide a plan that excluded red meat.  Fish, poultry, eggs 
and cheese were included in the “meat” exchange category of the eating plan (Appendix 
5).  Portion sizes for an exchange of each food type from each of the three food exchange 
groups are described in household measures.  The sizes were calculated using the guide to 
average portions (MAFF, 1993).  If advice to consume a variety of red meat was followed, 
the available dietary iron would range from 0.4mg to 3.6mg per 100g of which 50-80% 
would be haem iron
 (FSA, 2002).  Consumption of a variety of poultry and fish would give 
a range of dietary iron of 0.4 to 5.1 mg per 100g with a haem iron content of 20-40% 
(Lombardi et al., 2002, Rangan et al., 1997, Gomez-Basauri et al., 1992). 
 
Individual energy prescriptions ranging from a minimum of 1200 to a maximum 2600 kcal 
daily have been calculated in increments of 100 kcal per day using various combinations of 
these  exchanges.    For  each  of  the  exchange  groups  mean  energy  provision  and 
macronutrient composition were calculated.  The calculations were completed with the 
assumption  that  subjects  would  choose  to  eat  a  variety  of  foods  from  the  different 
exchange groups, and as such their intake should be as close as possible to the relevant 
dietary targets.   33 
2.3.10 Dietary Intake Assessment 
There  are  many  methods  available  to  assess  dietary  intake  and  all  have  limitations 
(Bingham 1987).  Prospective methods such as weighed intakes are expensive and time 
consuming for participants and require a certain degree of literacy.  The main disadvantage 
of retrospective methods, which includes food frequency questionnaires, is that they rely 
on memory and there may also be a tendency give desirable answers which may lead to 
over and under reporting of some food items.  All methods are subject to errors and biases 
from  misreporting.    Obese  subjects  consistently  provide  artificially  low,  incomplete 
inventories of their food intakes (Heitmann & Lissner 1995, Lara et al., 2004). 
 
The choice of method depends on the need and the research question.  Immediate short- 
term intake can be estimated from prospective methods (diaries, photographic weighed or 
household  measures)  or  using  24-hour  recall.    Longer  term  food  exposures  are  most 
commonly estimated from forms of dietary history or food frequency questionnaires.  For 
the present study in overweight/obese subjects it was recognised that quantitative estimates 
and  specifically  energy  intakes  would  be  unreliable  because  of  misreporting.    For  the 
purposes of this study it would have been difficult on practical grounds to carry out a 
prospective dietary analysis such as weighed intakes.  Previous research using weighed 
intakes had a high attrition rate (Leslie et al., 2004) and this was amongst people who in 
the main were not in employment.  As the present study population were mostly in full 
time employment the practicalities of weighing food at work, it was felt, was likely to 
increase the likelihood of attrition and increase misreporting. 
 
The aims of the dietary intake assessment in the present study were to determine if advice 
to  improve  intake  towards  UK  dietary  recommendations  had  been  implemented,  the 
relevant part of the diet being in the past.  Therefore dietary practices were assessed using   34 
the Dietary Targets Monitor (Lean et al., 2003), (Appendix 6).  This short food frequency 
questionnaire, developed for use in the Scottish Health Survey
 has been evaluated against a 
longer food frequency questionnaire (Bolton & Milne., 1991).  The evaluation was carried 
out in 1085 adults aged 25-64yrs from the Glasgow MONICA study population.  The study 
showed  that  the  Dietary  Targets  Monitor  had  the  capacity  to  monitor  dietary  change 
toward the adult food targets of fruit and vegetables starchy foods and fish (Lean et al., 
2003).  The advantages of using this method were ease and uniformity of administration, 
low cost and less burdensome for participants 
 
2.3.11 Study Power and Numbers 
The  principal  outcome  measure  was  change  in  serum  ferritin  at  24  weeks  post-
commencement of intervention.  Secondary outcome measures included changes in serum 
ferritin  at  12  weeks,  body  weight  at  12  and  24  weeks  and  meat,  fruit  and  vegetable 
consumption. 
 
Power calculations for serum ferritin were based on parameters derived from a published 
study of iron deficient women of child-bearing age (Patterson et al., 2001).  The calculated 
sample sizes were increased to compensate for an anticipated dropout rate of 30%.  A 
study based on 25 analysable patients per group (it was planned to recruit 33 per group 
allowing for 30% dropouts) would have power of 80% to detect as statistically significant a 
difference between the baseline to week 24 changes in the two study groups of 6.8 units in 
serum ferritin and would represent a clinically meaningful improvement.   
 
2.3.12 Statistical Analysis 
Data were managed and analysed using the software package SPSS (Version 14).     35 
Analysis of the primary outcome measure (serum ferritin) was based on analysis of co-
variance techniques (ANCOVA) using a generalised linear model (GLM) framework as 
the groups were unbalanced at baseline.  The mean differences (Standard Error (S.E), 95% 
confidence intervals and corresponding p-values are reported.  
 
Comparisons of weight change between the diet groups were made at 12 and 24 weeks 
using  two  sample  t-tests  and  corresponding  95%  confidence  intervals.    Paired  t-test 
analysis was used to examine within group differences at 12 and 24 weeks. 
The non-parametric Sign test was used to test whether a significant number of subjects in 
each group increased or decreased favourably their eating habits.  The effect of the diet 
programmes and meat advice were examined by estimated odds ratio.  
All analyses of iron status and weight were carried out on an “intention to treat” basis.  
Intention to treat analysis used the last recorded measurement, where available, for those 
who dropped out.  If the only recorded measurement was that at baseline zero change was 
assumed.    36 
 
 
 
 
 
Chapter 3 
Weight gain as an adverse effect of some 
commonly prescribed drugs: a systematic 
review   37 
This chapter represents a body of work from which a paper has been published.  Leslie et 
al, Quarterly Journal of Medicine, 2007; 100:395-404. (Appendix 8) 
 
3.1   Introduction 
Obesity continues to increase in prevalence (DOH 1995, SIGN 1996, WHO 1998).  In the 
UK around half of women and two thirds of men are overweight or obese (SHS 1998, 
NAO, 2001).  Recent Scottish data show that the figure for women has risen to 60% (SHS, 
2003).  In addition to being a major health problem in its own right, obesity is associated 
with a range of serious symptoms and co-morbid conditions.  The estimated cost to the UK 
Health  Service  of  obesity  and  related  conditions  at  present  is  immense  (NAO  2001, 
Walker, 2003).  If the rise in obesity continues it is thought that by the year 2010 one third 
of all adults in the UK will be obese (Williams, 1999), and the costs to health care services 
will have risen to an estimated £3.6 billion (NAO 2001).   
 
Obesity  is  a  consequence  of  energy  imbalance,  when  energy  intake  exceeds  energy 
expenditure over a prolonged period of time.  Social and environmental forces have a 
powerful  influence  over  energy  intake  and  expenditure  and  individuals  vary  in  their 
susceptibility to these influences due to genetic and biological factors.  It is the interaction 
of all these elements that gives rise to obesity (WHO, 1998).  Currently there are many 
prescription drugs in use that are associated with weight. For some, e.g. certain serotonin 
reuptake  inhibitors  and  oral  contraceptives,  the  evidence  to  support  an  effect  on  body 
weight  is  considered  less  consistent  (Keith  et  al.,  2006),  while  others  are  consistently 
associated with weight gain and are considered obesogenic (WHO, 1998, Lean 1998, Pijl 
&Meinders, 1996, Finer 1998) (Table 3.1).  This effect can  arise as a  consequence of 
differing mechanisms such as increased appetite (corticosteroids) or reduced metabolic rate 
(beta-adrenoceptor blockers) (Pijl & Meinders, 1996).  For some drugs weight loss may 
have occurred as a result of the underlying disease and recovery on effective treatment will   38 
include weight regain, which would not be considered an adverse effect.  However in many 
cases weight gain is an unwanted side effect.  These drugs are used in the management of 
chronic  disease  and  therefore  prescribed  on  a  long-term  basis.    Previous  research  has 
shown that 9% of adults attributed weight gain to drugs they were prescribed (Vossenaar et 
al., 2004).   
 
The  development  of  obesity  is  a  long-term  multifactorial  process  to  which  these 
obesogenic drugs play a contributory role.  The aim of this review was to quantify the 
effect that the drugs, listed in Table 1, consistently reported as obesogenic, and used in the 
treatment  of  chronic  disease,  may  have  as  an  adverse  effect  on  body  weight.    The 
hypothesis  to  be  tested  in  this  study  was  weight  gain  is  an  adverse  effect  of  some 
commonly prescribed drugs.  
 
The study was devised to address the following research questions: 
RQ1  Is weight gain an adverse effect of some commonly prescribed drugs? 
RQ2  Is the effect on body weight reported and quantified in studies examining these 
drugs? 
 
3.2  Results 
A total of 628 titles and abstracts were reviewed and 139 publications were retrieved and 
reviewed in greater detail.  From these 43 studies, involving a total of 25,663 subjects, 
were identified that met our inclusion criteria.  The main reasons for exclusion were: study 
duration less than 12 weeks, non- randomised study design, weight gain not reported or not 
quantified (Fig 3.1). 
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3.2.1 Valproate 
All four studies compared valproate with an alternative drug, no placebo controlled studies 
were  identified.    Comparison  was  made  with  olanzapine  in  the  treatment  of  bipolar 
disorder (Zajecka et al., 2002) and acute mania (Tohen et al., 2003).  The objective of both 
these studies was to compare the drugs in terms of efficacy and safety.  Biton et al., (2001) 
compared valproate with lamotrigine in patients with epilepsy.  The aim of the fourth study 
(Privitera  et  al.,  2003)  was  to  determine  the  efficacy  and  safety  of  topiramate  in 
comparison  with  cabamazepine  and  valproate  monotherapy  in  the  initial  treatment  of 
newly diagnosed epilepsy. 
Weight change was the primary outcome measure in only one study (Biton et al., 2001), 
and a secondary measure to assess safety in the remaining studies.  The mean dosage of 
valproate differed in each study (Table 3.2). 
 
3.2.2 Lithium  
Only one study fulfilled the inclusion criteria and compared lithium with carbamazepine as 
a  prophylactic  agent  in  bipolar  disorder  (Coxhead  et  al.,  1992).    The  main  outcome 
measure was relapse with weight gain recorded as an assessment of side effects.  The 
initial dose of lithium was 400mg twice daily.  
 
3.2.3 Atypical Antipsychotics  
In  three  studies  olanzapine  was  compared  with  placebo  in  the  treatment  of  alcohol 
dependence  disorder  (Guardia  et  al.,  2004)  and  borderline  personality  disorder 
(Bogenschutz  &  Nurnberg  2004,  Zanerinin  &  Frankenburg  2001).    Ziprasidone  was 
compared  with  placebo  in  the  treatment  of  schizophrenia  (Arato  et  al.,  2002).    In  the 
remaining  studies  comparison  was  made  between  an  atypical  antipsychotic  and  an 
alternative drug: clozapine, olanzapine, and risperidone with haloperidol (Czobor et al.,   40 
2002),  olanzapine  with  sodium  valproate  (  Zajecka  et  al.,  2002,  Tohen  et  al.,  2003), 
olanzapine with haloperidol (Tran et al., 1999, Lieberman et al., 2003), risperidone with 
amilsulpride  (Sechter  et  al.,  2002),  clozapine  with  chlorpromazine  (Lieberman  et  al., 
2003), olanzapine vs. aripiprazole (McQuade et al., 2004)
 and olanzapine vs. amisulpride 
(Mortimer et al., 2004).   
Only  two  studies  (Czobor  et  al.,  2002,  McQuade  et  al.,  2004),  specifically  examined 
weight change as a primary outcome, in the remainder of the studies clinical response was 
the primary outcome with weight change recorded as a means of assessing safety.   
 
3.2.4 Corticosteroids  
Only one randomised controlled trial was identified (Prummel et al., 1993) and compared 
prednisone with radiotherapy in the treatment of Graves’ ophthalmopathy.   
Comparison  of  the  efficacy  and  tolerability  of  the  treatments  was  the  objective  of  the 
study, clinical response being the primary outcome measure.  Weight change was recorded 
as a side effect. 
 
3.2.5 Insulin  
The studies included were restricted to the treatment of Type 2 diabetes.  In all studies 
insulin therapy alone was compared with either oral agents (Nathan et al., 1998, Tovi et 
al., 1996, UKPDS 1998) or with insulin plus oral agents (Chow et al., 1995, Yki-Jarvinen 
et al., 1992, Yki-Jarvinan 1997).  The dosage of insulin varied in each study and was 
calculated according to participant’s body weight and subsequently adjusted dependent on 
blood glucose results.  
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3.2.6 Sulphonylureas  
In two studies treatment with a sulphonylurea was compared with placebo only (Simonson 
et al., 1997, Bautista et al., 2003), with another oral hypoglycaemic agent and placebo in 
two studies (Segal et al., 1997, Johnstone et al., 1998), with insulin in two studies (Nathan 
et al., 1998, UKPDS 1998), and an alternative oral hypoglycaemic agent in three studies 
(Campbell  et  al.,  1994,  Marbury  et  al.,  1999,  Tan  et  al.,  2004).    Weight  change  was 
examined as a primary outcome measure in only one study (Campbell et al., 1994).  In the 
UKPDS study the main objective was to determine the risk of micro or macro-vascular 
complications with weight change recorded under adverse events.  The objective of the 
remaining studies was to determine efficacy, safety and tolerability, with clinical response 
as the primary outcome measure and weight change recorded under safety outcomes.   
 
3.2.7 Thiazolidinediones  
Three studies compared a thiazolidinedione with placebo in type 2 diabetic patients.  Patel 
et al., (1999) assessed the metabolic effects of 4 doses of rosiglitazone, Iwamoto et al 
(1996)  investigated  the  efficacy  and  safety  of  troglitazone  and  Wallace  et  al.,  (2004) 
examined  the  effect  of  pioglitazone  on  beta  cell  function  and  insulin  sensitivity.    The 
metabolic  effects  of  pioglitazone  were  compared  with  metformin  in  one  study 
(Schernthaner et al., 2004), in the final study pioglitazone was compared with glimepiride 
with regard to changes in glycaemic control and insulin sensitivity (Tan et al., 2004).  In 
all studies weight change was measured as a secondary outcome. 
 
3.2.8 Tricyclic Antidepressants  
All three studies compared the efficacy and tolerability of a tricyclic antidepressant with an 
alternative  anti-depressant.    Paroxitine  in  comparison  with  nortriptyline  (Weber  et  al., 
2000), bupropion compared with doxepin (Feighner et al., 1986) and mirtazapine with   42 
amitryptiline and placebo (Montgomery et al., 1998).  Weight change was the primary 
outcome measure in one study (Weber et al., 2000), and assessed as an adverse event in the 
other two.  The dosage of tricyclic antidepressant was not reported in one study (Weber et 
al., 2000) and differed in the other two.  
 
3.2.9 Beta- Adrenergic blocking agents  
Two studies compared the effect on lipid profiles between a chosen beta-blocker and an 
alternative anti-hypertensive agent: captopril vs. metoprolol (Foss & Jensen, 1990) and 
nifedipine vs. atenolol (Houston et al., 1991).   The effect of long-term treatment with 
propranolol on body weight study was the main outcome in one study (Rossner et al., 
1990).  Two studies compared treatment with a beta/blocker with bendroflumethiazide, one 
investigated the metabolic effects (Berglund et al., 1986), the other compared the effects 
on mortality (Wikstrand et al., 1988).  Wilhelmsen et al., (1987) compared beta-blocker 
treatment  with  diuretic  treatment  to  determine  difference  in  the  incidence  of  non-fatal 
myocardial infarction, coronary heart disease mortality and total mortality. 
 
3.2 10 Cyproheptadine 
No studies were identified that fulfilled the inclusion criteria. 
 
3.2.11 Methodological quality of included studies 
All studies included in this review were described as randomised however in the majority 
of papers (72%) the methods of randomisation and concealment were not described.  In 
one study (Chow et al., 1995) the method of randomisation (consecutive and alternate) was 
inadequate (CRD Guidelines 2001).  In 11 studies the method of randomisation was clearly 
described and considered adequate.  Inclusion and exclusion criteria were clearly described 
in all studies.  Intention to treat analysis was carried out in 51% of studies.   43 
3.2.12 Weight Change 
In the majority of studies weight change was not a primary outcome measure but was 
measured and recorded under safety outcomes.  Weight change was a primary outcome 
measure in only 6 studies
 (Biton et al., 2001, Czobor et al., 2002, McQuade et al., 2004, 
Campbell et al., 1994, Weber et al., 2000, Rossner et al., 1990).  The effects on body 
weight  differed  greatly  amongst  the  different  categories  of  drugs.    In  the  majority  of 
studies weight gain was the result of treatment with some of the greatest weight gains seen 
in subjects prescribed anti-psychotic medications.  However in some studies weight loss 
was observed (Table 3.2).   
 
Six studies investigated whether weight gain was dose related.  Results varied with three 
studies reporting no relationship between drug dosage and weight gain (Biton et al., 2001, 
Arato et al., 2002, Czobor et al., 2002).  Some correlation was observed between dosage of 
insulin and weight gain (Chow et al., 1995, Yki-Jarvinen, 1992).  One study (Patel et al., 
1999) suggested that a clinically significant increase in body weight might be observed at 
higher doses of rosiglitazone.  
 
3.3  Study Limitations 
The  drugs  included  in  the  present  review  were  those  consistently  reported  in 
medical/scientific literature, used in the treatment of chronic disease
 and believed to affect 
weight (WHO 1998, Keith et al., 2006, Lean, 1998, Pijl & Meinders, 1996, Finer, 1998).  
We acknowledge that many other drugs prescribed today may also affect weight.  Few 
studies included in the review examined weight change as a primary outcome and in many 
instances  the  variability  of  weight  change  was  not  reported.    Studies  that  primarily 
investigated the effect of a combination of “obesogenic” drugs were excluded, however it 
was not always possible to be certain that other drugs known to favour weight gain were   44 
not also being taken.  However the process of randomisation should have ensured that any 
such confounding effect would have been similar in all groups. 
 
3.4  Discussion 
Weight change occurs over time and against a background of progressive weight gain in 
the “normal” population.  There is no ideal time to examine the possible obesogenic effects 
of drugs.  It can be assumed that most such drugs will have a most marked effect early in 
treatment, reaching a plateau effect by 6-12 months (although all healthy subjects are likely 
to continue to gain weight at around 1kg per year) (Hietman & Garby, 1999, Phelan et al., 
2003). 
 
If the underlying disease for which the drug was prescribed has caused weight loss then 
recovery on effective treatment will include weight regain.  The primary treatment of Type 
1 diabetes is an obvious example.  This was not considered an obesogenic effect and such 
studies were excluded by our own inclusion criteria. 
 
The effect of the drug treatment on body weight was reported in all of the studies in this 
review and provides evidence that weight gain is associated with some drugs and is a 
major and continual burden on public health.  All of the drugs included in this review are 
used in the treatment of chronic disease.  In the UK it is estimated that around 2.5 million 
people have been diagnosed with coronary heart disease (BHF 2008) and beta-blockers, 
unless contraindicated, have a prominent role in its management ( NICE 2000, SIGN 2001, 
SIGN 2001).  Valproate is one of the first line treatments for epilepsy (SIGN 2003) and 
also used in the treatment of manic episodes associated with bipolar disorder.  In Scotland 
around 20,000 – 40,000 people have active epilepsy with about 2-3,000 new cases per year   45 
(SIGN 2003).  In England 380,000 people suffer from the disease (one in 130 people) 
(DOH  2003).    Bipolar  disorder  is  the  third  most  common  mood  disorder  after  major 
depression  and  schizophrenia,  and  affects  around  1%  of  the  population  (NICE  2002).  
Around 1.3 million people in the United Kingdom suffer from either Type 1 or Type 2 
diabetes  (BHF  200).    In  the  light  of  these  figures  the  number  of  individuals  in  the 
population  receiving  treatment  with  an  obesogenic  drug  is  potentially  quite  high.    In 
Scotland  alone  the  number  of  prescriptions  dispensed  for  beta-blockers  and  1tricyclic 
antidepressants between 2004 and 2005 exceeded one and two million respectively (Table 
3.3),  (Audrey  Thompson,  Medicines  Management  Advisor,  NHS  GG&C,  personal 
communication).  
 
It is generally accepted that during adult life most people will gain weight.  The rate at 
which weight is gained varies but a 0.5-1kg gain per year is considered average in the 
general population (Heitmann & Garby, 1999, Phelan et al., 2003).  In some studies in the 
present review weight gain in excess of this was observed over a much shorter duration, in 
particular those involving anti-psychotic drugs.  Olanzapine and clozapine were associated 
with the greatest weight gains, a finding that concurs with previous reviews in this area 
(Allison et al., 1999, Ness-Abramof et al., 2005).  The weight gains with beta-blocker 
therapy were relatively small but more marked in those prescribed propranolol.  Previous 
research has identified propranolol as the beta blocker most likely to cause weight gain 
(Cheskin et al., 1999, Sharma et al., 2001).  
 
In  the  UK  at  present  a  significant  proportion  of  the  population  are  considered  either 
overweight or obese (NAO 2001, SHS 2003).
  It is therefore likely that prior to treatment 
with a drug known to favour weight gain many individuals will already be overweight and 
struggling to avoid further gain.  The additional effect of obesogenic drug therapy may tip 
the  balance  to  increase  BMI  towards  the  obese  category  or  be  sufficient  to  make  co-  46 
morbidities clinically apparent.  Given the common and long-term use of many of these 
drugs it is likely that they play a significant contributory role in the increasing prevalence 
of obesity.   
 
Non-compliance with any drug therapy is a widespread problem (Wertheimer & Santella, 
2003) and around half of patients prescribed long-term medication for the management of 
chronic diseases do not comply fully with treatment (Perkins, 2002).  Poor compliance 
with drug therapy may lead to a worsening of the underlying condition and contribute to 
increased health care costs (Osterberg & Blasche, 2005).  Non-compliance is reported as 
an issue with many of the drugs included in this review (Osterberg & Blasche, 2005, Hertz 
et al., 2005, Lowry et al., 2005, Weiden et al., 2004) and the weight gain associated with 
them may contribute to this.  For those prescribed anti-psychotic medication weight gain is 
acknowledged as a major cause of non-compliance (Weiden et al., 2004).  It is unclear 
whether this known side effect is routinely discussed with patients prior to prescription but 
this should be done on medico-legal grounds.  The treatment of anti-psychotic induced 
weight gain is now considered a treatment priority and research on approaches to address 
this  is  a  growing  area  (Werneke  et  al.,  2003,  Ohlson  et  al.,  2004,  Ball  et  al.,  2001, 
Vreeland et al., 2003, Littrell et al., 2003).  It would seem greatly preferable to discuss the 
probability of weight gain as a side effect and to provide effective advice and support to  
avoid weight gain.  For a number of the drugs classes included weight management should 
form  an  essential  part  of  treatment  for  the  underlying  disease  e.g.  Type  2  diabetes, 
hypertension and access to dietitians should be routine.  For other drugs – notably anti-
psychotics - provision of dietary advice is a new consideration (Lean & Pajonk, 2003).   
 
This review provides evidence of the weight gain potential of some common drugs.  It is 
perhaps only now, in light of the present epidemic of obesity, that the negative effect on 
body weight is a more pertinent issue.  Body weight and height are routinely recorded in   47 
virtually all clinical trials, but seldom reported.  The potential of weight gain should be 
discussed with patients prior to the institution of therapy both for medico-legal grounds 
and to ensure that weight maintenance is promoted and adhered to.   
 
Healthy eating advice, appropriate for all sectors of the population (www.food.gov.uk), 
should be advocated to those prescribed obesogenic drugs and may help minimise weight 
gain  in  the  first  instance.    For  those  who  experience  weight  gain  the  600  kcal 
individualised ED (Lean & James, 1986) approach, discussed previously, which advocates 
a balanced diet based on healthy eating advice, is an appropriate approach for weight loss. 
It is recommended in the recently published NICE guidelines (NICE 2006) and its effects 
on nutritional status are investigated in a later chapter of this thesis (Chapter 5).  
 
3.5   Conclusion 
This study has provided answers to the following research questions: 
RQ1  Is weight gain an adverse effect of some commonly prescribed drugs? 
RQ2  Is the effect on body weight reported and quantified in studies examining these 
drugs? 
It has shown that a range of commonly prescribed drugs do cause weight gain (RQ 1).  The 
effect is relatively modest for most drugs but few pharmaceutical trials have reported data 
on weight change adequately (RQ2).  It is a most unwelcome side effect and liable to be 
suppressed in publications.  Patients often attribute weight gain and obesity to prescription 
drugs (Vossenaar et al., 2004).  They are often correct.  Some individuals gain much more 
than the mean and an underlying weight problem may exacerbate the problem.  These 
drugs almost certainly impede weight management although specific evidence is lacking.  
If  these  drugs  are  prescribed  then  patients  need  to  be  warned  about  side  effects,  and 
advised  on  how  to  avoid  weight  gain.    Again  no  specific  research  had  evaluated   48 
preventative interventions, but the approaches examined in the remainder of this thesis 
would be appropriate. 
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Table 3.1 Drugs known to favour weight gain  
Drug  Main use 
Insulin, sulphonylureas, thiazolinidiones  Diabetes 
Beta blockers  Hypertension 
Corticosteroids  Inflammatory disease 
Cyproheptadine  Allergy, hay fever 
Antipsychotics  Psychosis 
Sodium Valproate  Epilepsy 
Tricyclic antidepressants  Depression 
Lithium  Bipolar disorder 
WHO, 1998; Keith et al., 2006; Lean, 1998; Pijl & Meinders, 1996; Finer, 1998 
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Figure 3.1 Flowchart of progress of papers through the review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant papers 
identified and screened for 
retrieval (n=628) 
Papers excluded (n=489) 
Reasons: 
Not RCT (282) 
Study duration<12 weeks (52) 
Not adults (32) 
Combination therapy (28) 
Weight gain not reported/quantified (5) 
No comparator (18) 
Study aim weight loss (16) 
Weight gain not considered adverse effect (18) 
Drug under review not included in study (38) 
Papers retrieved for more 
detailed evaluation (n=139) 
RCT’s included in 
review (n=43) 
Papers excluded (n=96) 
Reasons: 
Not RCT (37) 
Study duration<12 weeks (10) 
Not adults (1) 
Combination therapy (5) 
Weight gain not reported/quantified (30) 
No comparator (3) 
Weight self- reported (2)) 
Drug under review not included in study (1) 
Not drug naïve prior to study (2)   
Duplicate publication (5)   51 
Table 3.2 Drugs and their effect on body weight 
Drug  Reference  Condition  Follow 
up 
(wks) 
n  Dose  Weight change (kg) 
Valproate  Zajecka 2002
 #  Bipolar disorder  12  120  2115mg/d*  +2.5** 
  Biton 2001
  Epilepsy  32  141  1822mg/d*  +5.8 (SD 4.2) 
  Tohen 2003
  Bipolar disorder  47  251  1500mg/d*  +1.2(SE 1.2) 
  Privitera 2004
  Epilepsy  26  621  1250mg/d  +2.0** 
Lithium  Coxhead 1992
  Bipolar Disorder  52  32  > 400mg/d  +4.0** 
Clozapine   Czobor 2002
  Schizo-affective 
disorder 
14   151  200-800mg/d  +4.2 (SD 4.7) 
  Lieberman 2003
  Schizophrenia  52  160   < 400 mg/d  +9.9** 
Olanzapine  Zajecka 2002
 #  Bipolar disorder  12  120  14.7mg/d*  +3.9** 
  Lieberman 2003
  Psychosis  12  263  9.1mg/d*  +7.1 (SD 6.1) 
  Czobor 2002
 #  Schizo-affective 
disorder 
14  151  30.4mg/d*  +5.4 (SD 4.6) 
  Zanerini 2001
  Borderline  personality 
disorder 
24  28  5.3mg/d*  +2.8 (SD 5.7)   52 
Drug  Reference  Condition  Follow 
up 
(wks) 
n  Dose  Weight change (kg) 
  Tohen 2003
 #  Acute Mania  47  251  16.2mg/d*  +2.8** 
  Tran 1999
  Schizo-affective 
disorder 
51  110  11.5mg/d*  +5.0 (SD 7.3) 
Olanzapine  Guardia 2004
  Alcohol dependence  12  60  5-15mg/d  +4.3** 
  Bogenshutz 2004
  Borderline  personality 
disorder 
12  40  2.5-20mg/d  +3.7 (SD 3.4) 
  McQuade 2004
  Schizophrenia  26  317  10-20mg/d  +4.2** 
  Mortimer 2004
  Schizophrenia  26  377  5-20mg/d  +3.9 (SD 5.3) 
Risperidone  Czobor 2002
 #  Schizo-affective 
disorder 
14  151  7.9mg/d*  +2.3 (SD 2.8) 
  Sechter 2002
  Schizophrenia  24  309  4-10mg/d  +2.1** 
Ziprasidone  Arato 2002
  Schizophrenia  52  294  40mg/d 
80mg/d 
160mg/d 
-2.7** 
-3.2** 
-2.9** 
Prednisone  Prummel 1993
  Graves 
Ophthalmopathy 
24  56  Decreasing 
60-2.5mg/d 
+2.0**   53 
Drug  Reference  Condition  Follow 
up 
(wks) 
n  Dose  Weight change (kg) 
Insulin  Yki-Jarvinen 1992
  Type 2 Diabetes  12  153   2 injection 
multiple 
injection 
+1.8 (SD 0.5) 
+2.9 (SD 0.5) 
  Chow 1995
  Type 2 Diabetes  26  53  2 injection  +5.2(SD 4.1) 
  Nathan 1988
#  Type 2 Diabetes  36  31  1 injection  +6.6** 
 
  Tovi 1996
  Type 2 Diabetes  52  35  2 injection  +3.9**  
  Yki-Jarvinen 1997
  Type 2 Diabetes  52  100  2-4 injection  +5.1 (non-obese) (SD 0.6) 
            +4.5 (obese)(SD 1.1) 
  UKPDS 1998
#  Type 2 Diabetes  10yrs  3867  1-2 injection  ~+6.5** 
Glipizide  Simonson 1997
  Type 2 Diabetes  16  143 
204 
5-60mg/d 
5-20mg/d 
-0.3 (SD 0.2) 
-0.1 (SD 0.1) 
  Campbell 1994
  Type 2 Diabetes  52  48  5-30mg/d  +2.6** 
  Marbury 1999
  Type 2 Diabetes  52  576  0.5-12mg/d  +3.6**   54 
Drug  Reference  Condition  Follow 
up 
(wks) 
n  Dose  Weight change (kg) 
  Johnstone 1998
  Type 2 Diabetes  52  411  1.25-20mg/d  +2.3** 
  Nathan 1988
 #  Type 2 Diabetes  36  31  2.5-10mg/d  +3.8** 
Glimepiride  Bautista 2003
  Type 2 Diabetes  14  70  1-4mg/d  +2.3** 
  Tan 2004
 #  Type 2 Diabetes  52  244  2-8mg/d  +0.8** 
Glibenclamide  UKPDS 1998
 #  Type 2 Diabetes  10 yrs  3867  2.5-20mg/d  ~+4.0** 
  Segal 1997
  Type 2 Diabetes  24  201  3.5mg/qid  +1.4** 
Chlorpropamide  UKPDS 1998
#  Type 2 Diabetes  10yrs  3867  100-500mg/d  ~+5.0** 
Troglitazone  Iwamoto 1996
  Type 2 Diabetes  12  284  400mg/d  +0.06(SD 1.6) 
Rosiglitazone  Patel 1999
  Type 2 diabetes  12  380  0.05mg/d 
0.25mg/d 
1.0mg/d 
2.0mg/d 
-0.95** 
-0.54** 
+0.18** 
+0.36** 
Pioglitazone  Wallace 2004
  Type 2 diabetes  12  30  45mg/d  +0.70(SE 0.6) 
  Tan 2004
 #  Type 2 diabetes  52  244  15-45mg/d  +1.5** 
  Schernthaner 2004
  Type 2 diabetes  52  1199   <45mg/tid  +1.9**   55 
Drug  Reference  Condition  Follow 
up 
(wks) 
n  Dose  Weight change (kg) 
Nortriptyline  Weber 2000
  Depression  12  32   n/a  +3.7(SD 2.3) 
Doxepin  Feighner 1986
  Depression  13  147  100-225mg/d  +2.7** 
Amitriptyline  Montgomery 
1998
(51) 
Depression  104  217  max 280mg/d  +1.7(SD 4.1) 
Atenolol  Houston 1991
  Hypertension  13  49  56mg/d*  +1.0** 
Atenolol or 
metoprolol 
Wilhelmson 
1987
(57) 
Hypertension  45mnths  6569  100/200mg/d  +1.1** 
Metoprolol  Wikstrand 1988
  Hypertension  208  3234  174mg/d*  +1.5** 
  Foss 1990
  Hypertension  26  114  50-200mg/d  +0.5(females)** 
+0.7(males)** 
Propranolol  Rossner 1990
  Post myocardial 
infarction 
52  3837  Not stated  +2.3** 
  Berglund 1986
  Hypertension  10yrs  106  80mg/bd*  -0.6** 
* mean dose 
** SD or SE not reported 
      # denotes duplicate reporting of studies as a result of the comparator in each study 
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Table 3.3 Prescribing by GP practices in Scotland April 2004- March 2005 
 
Drug Class  No of prescriptions 
Beta blockers (BNF 2.4)  2,936,456 
Atypical antipsychotics  275,114 
Lithium   81,252 
Sodium Valproate  193,064 
Tricyclic antidepressant  1,134,611 
Intermediate and long acting insulins  352,632 
Short acting insulins  105,207 
Suphonylureas  442,833 
Pioglitizone  36,898 
Rosiglitizone  65,458 
Glucocorticoid therapy (BNF 6.3.2)  517,366 
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Chapter 4 
 
Weight management: a survey of current 
practice in secondary NHS settings in 2004 
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This chapter represents a body of work from which a paper has been published.  Leslie et 
al, Journal of Evaluation in Clinical Practice, 2005; 11:462-467.  (Appendix 9) 
 
4.1   Introduction 
The estimated cost to the health service of obesity and related conditions, compared to 
people  with  ideal  or  normal  weight,  is  immense  (NAO  2001)  and  the  development  of 
strategies for the prevention and treatment of obesity and overweight is now a priority for 
health promotion and education (DOH 1992., WHO 1998,).  Given the large numbers of 
overweight and obese subjects (43% and 22% of the entire adult UK population), and its 
wide variety of clinical manifestations, it is recommended that weight management should 
usually be undertaken in primary health care, community or commercial sectors
 (SIGN 
1996).  Attempts are being made to establish a structured approach to weight management 
in  the  primary  care  setting  as  a  recent  audit  has  shown  that  both  the  identification  of 
obesity  and  overweight  and  its  subsequent  management  are  at  present  sub-optimal 
(Counterweight Project Team 2004a).   
 
In addition to being a major health problem in its own right, obesity contributes to a range 
of  co-morbid  conditions,  importantly  including  type  2  diabetes  mellitus,  hypertension, 
hyperlipidaemia, coronary heart disease, stroke, several major cancers, back-pain, arthritis 
and depression (WHO 1998).  Many of those diagnosed with co-morbid conditions such as 
diabetes, hypertension, coronary heart disease and depression are likely to be prescribed 
drugs know to favour weight gain (Leslie et al 2007). 
 
The  management  of  most  of  these  conditions  is  conventionally  co-ordinated  from  a 
secondary  care  specialist  setting.    This  setting  provides  an  opportunity  to  identify  and 
initiate management of an underlying weight problem if it is contributing to pathology.          59 
 
However it is unclear if, or how, the management of obesity is currently addressed in this 
setting  and  what  links  exist  with  primary  care  to  ensure  comprehensive  and  effective 
management.   
 
The  aim  of  this  study  was  to  determine  the  current  practices  in  relation  to  weight 
management  currently  provided  for  overweight/obese  patients  attending  different 
secondary care outpatient clinics.  The study was devised to address the following research 
questions: 
RQ3  Are formal protocols to routinely identify and manage overweight/obese patients in 
place in secondary care clinics? 
RQ4   Is height and weight routinely measured in secondary care clinics? 
RQ5  What steps are taken to manage patients who are identified as overweight or obese? 
 
4.2   Participants and Methods 
The study was carried out in 3 NHS Trust areas in Scotland, between January and March 
2004.  Ethical approval was sought from each trust however formal ethical approval was, 
in  each  case,  deemed  unnecessary,  as  neither  the  process  nor  the  questionnaire  raised 
ethical issues. 
 
Questionnaires were sent to 100 consultant clinicians working in a range of specialist areas 
(endocrinology, orthopaedics, obstetrics and gynaecology, cardiology, general medicine, 
respiratory  medicine,  rheumatology,  general  surgery)  in  five  District  General  Hospitals 
within  the  three  trust  areas.    These  hospitals  were  chosen  to  represent  a  range  of 
rural/urban  and  socio-economic  environments.   One  reminder  letter,  including  a  repeat 
questionnaire, was sent to non-responders after 2 weeks.   
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The  postal,  self-completed  questionnaire,  which  had  been  piloted  with  9  clinicians, 
comprised 8 questions to determine:  
a)  if a formal protocol was in place to routinely identify and manage overweight/obese 
patients within each specialty 
b)  if no protocol in place the reasons for this were sought  
c)  if measurements of height and weight were routinely made 
d)  the actions taken, by the clinician, if a patient was considered overweight/obese e.g. 
referral to dietitian etc 
e)  whether it was felt that overweight/obesity affected outcomes or treatment within 
each specialty field 
f)  attitudes to prescribing anti-obesity drugs. 
Respondents who indicated they had a weight management protocol in place were asked to 
enclose a copy with their completed questionnaire 
 
Two models of treatment were also suggested for possible development, Model A – to 
identify treat and manage overweight/obesity within each medical sub-specialty, or Model 
B to identify and then refer to a specialist obesity clinic (Appendix 1).  Those surveyed 
were asked to indicate their preference. 
 
4.3   Results 
4.3.1  Pilot study 
All pilot questionnaires were returned completed.  Three respondents reported having a 
protocol in place but did not return a copy of this.  Height and weight were routinely made 
in  55%  of  responses,  referral  to  a  dietitian  was  the  preferred  option  if  a  patient  was 
considered  overweight,  all  agreed  that  overweight/obesity  affected  treatment  outcomes.  
Model A was the model of choice for 44% of respondents.           61 
 
None of the respondents suggested the addition or omission of any questions.  Thus it was 
felt that the questionnaire was acceptable, and the questions unambiguous.  No changes to 
the questionnaire were made in light of the pilot. 
 
4.3.2  Main Survey 
The  overall  response  rate  was  55%,  response  by  specialty  was:  endocrinology  2%, 
orthopaedics  11%,  obstetrics  and  gynaecology  11%,  cardiology  2%,  general  medicine 
12%, respiratory medicine 3%, general surgery 14%.  Only 9% (5) of respondents reported 
having a protocol in place for the management of patients who were overweight or obese, 
(diabetes/endocrinology, renal medicine, general surgery, cardiology).  However, none of 
the clinicians enclosed a copy of their protocol with their completed questionnaire. 
 
4.3.3   Reasons for having no current protocol for weight management 
Overall,  the  opinion  of  51%  of  respondents  was  that  weight  management  (including 
obesity  treatment)  should  be  undertaken  by  a  specialist  service  either  run  by  general 
practitioners, or by clinicians in a secondary care setting (Table 4.1).  Lack of expertise and 
inaccessibility to expertise were cited frequently as reasons for having no protocol in place.   
 
Twenty two percent of responding clinicians felt that weight/obesity management was not 
important to health care in general (gastroenterology, general medicine, general surgery, 
obs/gyn, cardiology) or not important to their specialist area (gastroenterology, respiratory, 
colorectal surgery, breast/general surgery, urology, thoracic surgery).   
 
Other specific reasons for not having a protocol in place included: 
“not aware that specialist advice/treatment is necessary for weight loss”  
“over-weight is the responsibility of the patient”          62 
 
“previous attempts at a weight management strategy in a general surgery context has often 
proved fruitless, we now just get on with it”  
“waiting times to see dietitian, and I find that most patients attending dietitian are not 
motivated enough to lose weight”  
 
4.3.4  Recording of height and weight 
Both height and weight were reported as being routinely recorded in outpatient clinics in 
just over half the responses (52%). Weight only was measured in a further 5% of cases.  
The outpatient clinics not measuring height and weight, and so unable to calculate body 
mass index, included: orthopaedics, general surgery, obs/gyn, gastroenterology, respiratory 
medicine, general medicine, colorectal surgery, upper GI surgery, cardiology, and urology.  
 
4.3.5  Action  taken  by  the  clinician  if  they  considered  a  patient  to  be 
overweight/obese 
Overall, if a patient was considered overweight or obese, referral to the hospital dietitian 
was  the  most  frequently  selected  option  (Table  4.2),  and  included  the  clinicians  who 
reported having a protocol in place, and also those who did not routinely measure patient’s 
height and weight.  Among those who selected this option, 25 indicated that this would be 
their only course of action, while 10 indicated that they may also refer a patient back to 
their GP for treatment.  Very few clinicians said that they would take no action.  Referral 
to a specialist obesity physician was not considered by any of the clinicians.  
 
Almost  all  consultants  (94.4%)  agreed  that  overweight/obesity  affected  outcomes  and 
treatment  within  their  area  of  expertise.    This  included  all  those  who  said  that 
weight/management was not a priority for health care in general, and the majority who said 
it was not important to their specialist area (71.4%). 
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About one in five consultants responded that they were happy to prescribe anti-obesity 
drugs,  however  81.5%  said  they  would  not  currently  be  comfortable  prescribing  them 
within their own specialist practice.  A number of reasons were given for this, the most 
frequently cited being lack of experience in the use of these drugs.  Other reasons for not 
using these drugs included: 
“patients’ need to consume less calories not take drugs at the NHS’s expense, does not 
treat the cause of obesity which is a basic arithmetic problem – calories in > than calories 
out”  
“no  confidence  in  these  methods,  believe  lifestyle  modification  is  the  cornerstone  of 
management and anti-obesity drugs should be dealt with by a specialist”  
“patients’ treated with drugs would need follow-up and I cannot follow-up patients for 
weight management purposes alone”  
“I do not have the time or inclination to manage obesity within my specialty”  
 
About twice as many clinicians chose Model B (identify and refer to a specialist obesity 
clinic) than Model A (identify treat and manage overweight/obesity within each medical 
sub-specialty) as the model for potential development (64% v 31%, p< 0.0001, x
2 test).  
Two  consultants  wanted  neither  model  the  additional  comment  from  one  being  “no 
evidence either would work – waste of money”.  On the other hand the view of another 
consultant was that “either model would represent an improvement, however, what was the 
evidence for either, and perhaps A, or B should be a locally performed trial”. 
 
4.4   Discussion 
It  is  forecast  that  by  the  year  2010  one  third  of  UK  adults  will  be  clinically  obese 
(Williams, 1999)
 and the costs to health care services are expected to rise to an estimated 
£3.6  billion  (NAO,  2001).    The  contribution  of  overweight  to  type  2  diabetes  and 
metabolic syndrome is such that weight gain is overtaking smoking as a cause of coronary         64 
 
heart disease and cancers (House of Commons Health Committee 2004).  The development 
of strategies for the prevention and treatment of obesity is now a high priority.  Primary 
care is usually identified as the most appropriate setting for weight management (SIGN 
1996,  R  Coll  Phys  2004,  NICE  2006)
  and  there  is  little  NHS  activity  related  to  the 
management  of  obesity  outside  general  practice  (NAO  2001).    Previous  research  has 
shown that obesity is common in many different outpatient clinics (Cleator et al., 2002),
 
and contributes to pathology and distress in many ways.   
 
The present survey showed clearly that most hospital specialists recognise that obesity is 
contributing  to  their  patients’  ill  health,  but  suggests  that  they  perceive  little  value  in 
weight management.  This is at odds with the literature and may reflect the unrealistic 
goals of obese patients to become thin.  Five to ten percent weight loss brings multiple 
health  benefits  (Goldstein,  1992)  and  is  now  an  internationally  accepted  target  for  the 
short-term weight loss phase of weight management (SIGN 1996, NIH 1998, R Coll Phys 
1998, NICE 2006).  Taking the example of type 2 diabetes alone, which now affects 5-10% 
of all 60 year olds (SEDH 2000) and as much as 20-30% of older Asian groups (McKeigue 
et al., 1998), 5-10% weight loss with diet and exercise will reduce new diabetes by 58% 
over  4  years  (Tuomilehto  et  al  2001,  DPP  2002).    The  addition  of  orlistat  –  a  non-
absorbable  anti-obesity  agent  –  reduces  new  diabetes  by  a  further  38%  over  4  years 
(Torgerson et al., 2004).  Modest weight loss also improves lung function, reduces the 
frequency of sleep apnoea, alleviates osteoarthritis and improves ovarian function (WHO 
1998).  There are strong arguments for urging clinicians to incorporate weight management 
within their specialty practices.   
 
Clinicians who reported having a formal weight management protocol in place were in the 
minority.  None forwarded a copy of the protocol suggesting that it may not in fact be         65 
 
documented or formalised.  The usual course of action taken by these clinicians if a patient 
was considered overweight/obese was referral to the hospital dietitian.   
 
Most clinicians felt they could not currently provide weight management within their areas 
of specialisation and just over a quarter indicated that they would refer patients back to 
their own GP for weight management.  However previous research has shown that GPs 
also feel that they do not have the expertise or resources to manage obesity/overweight 
(Hankey et al., 2004).  Training is clearly an issue as clinicians feel they do not have the 
necessary skills to treat those who are over-weight/obese and it is acknowledged that “little 
has been done to expand nutrition into the core training of all health professionals” (R Coll 
Phys, 2004).  
 
Identifying  those  who  are  overweight/obese  is  a  crucial  step  in  its  management,  and 
secondary care clinics are considered a good opportunity to identify patients (Cleator et al., 
2002).  In the present study almost half of clinicians reported that height and weight were 
not recorded routinely at their clinics.  Therefore the opportunity to identify and manage 
those who are overweight/obese is, in many cases, lost.  Lack of expertise and or access to 
expertise was commonly cited as a reason for not having a protocol in place.  This may 
discourage clinicians from taking time to identify overweight/obese patients if they feel 
that effective management is not accessible or available.  
 
There are clearly different ways forward.  Most clinicians favoured Model B, (identify and 
refer  to  specialist  obesity  clinic),  for  potential  development.    However  a  third  of 
respondents felt that they could valuably tackle obesity within their specialist practice.  A 
low cost approach, by using staff and resources already available within each specialty, 
would be to build on this substantial minority.  The comment of one clinician that evidence 
for the development of either model was lacking and research was needed is pertinent.          66 
 
Since there is no established model of best practice in specialist secondary care of obesity 
in  routine  NHS  services  (as  distinct  from  isolated  academic  units)  the  best  plan  is  to 
establish programmes on the basis of best available evidence, but with a closed-loop audit 
to  permit  improvements  to  be  incorporated.    This  needs  to  be  established  on  the 
background of better incentives to enhance the first-line management of obesity in primary 
care  –e.g.  Counterweight  (Counterweight  Project  Team,  2004b).    A  specialist  obesity 
service  is  about  to  be  piloted  within  the  Greater  Glasgow  Health  Board  area  and  will 
provide  much  needed  evidence  for  the  development  of  effective  obesity  management 
strategies in routine clinical care.   
 
4.4.1 Limitations 
The present study was limited both geographically and in terms of the survey numbers.  
The response rate may also be considered inadequate, increasing the potential for non-
responder  bias.    Previous  research  regarding  response  rates  to  postal  questionnaires 
amongst  health  professionals,  including  hospital  consultants  found  that  response  rates 
varied from 58-83% (Cartwright, 1978).  However, it is thought that bias can occur even a 
with high response rate (Barclay et al., 2002).  In the present survey it is possible that equal 
numbers  of  non-responder  were  passionate  for  and  against  weight  management.    The 
consensus amongst a wide range of hospital specialists suggests that the views reported 
may reflect those nationally. 
 
4.5   Conclusion  
Effective prevention and management are required to challenge the obesity epidemic.  This 
will require the involvement of both primary and secondary care NHS settings.  This study 
has provided a partial answer to research questions 3, 4, and 5:          67 
 
RQ3  Are formal protocols to routinely identify and manage overweight/obese patients in 
place in secondary care clinics? 
RQ4   Is height and weight routinely measured in secondary care clinics? 
RQ5  What steps are taken to manage patients who are identified as overweight or obese? 
 
NHS secondary care consultants are clearly concerned about obesity and its impact on their 
specialty field.  Most have no clear strategy and would like one (RQ 3).  The opportunity 
to identify patients who are overweight or obese is frequently missed as height and weight 
are  frequently  not  measured  (RQ  4).    Some  consultants  are  willing  to  take  on  weight 
management, but others are ignorant of its value and remits.  While acknowledging the 
adverse effects of obesity in clinical practice, many clinicians still regard this as an area for 
which they feel unskilled and are under resourced (RQ 5).  It is encouraging that, despite 
this,  about  one  third  of  all  consultants  felt  prepared  to  incorporate  obesity  and  weight 
management within their routine specialist practice. 
This part of this thesis would be considered Phase 2 Translational Research (Lean et al., 
2008).  It uses mainly a quantitative approach, with some qualitative aspects.  The results 
indicate  that  the  efficacious  and  safe  methods  developed  for  weight  management 
(including, for example the dietary intervention reported in Chapter 5) still need to be 
presented and evaluated in routine secondary care practice, if they are to be effective and 
sustainable.  This study did not ask about the use of obesogenic drugs (Chapter 3) but that 
would be one issue which secondary care consultants cannot ignore ethically as many of 
their patients are likely to be prescribed one or some of these drugs.         68 
 
 
 
 
Table 4.1 Reasons for not having a formal weight/obesity management protocol 
Reasons  n (%)* 
Weight/obesity management not a priority for health care 
in general 
5 (9.1) 
Weight/obesity  management  not  important  to  this 
specialist area 
7 (12.7) 
Expertise  not  available  to  treat  weight/obesity 
management within this specialist area 
21 (38.2) 
Personnel skilled in weight management inaccessible  13 (24.0) 
Weight/obesity management best undertaken by dedicated 
secondary care obesity specialist service 
13 (23.6) 
Weight/obesity  management  should  be  undertaken  by  a 
GP specialist service 
15 (27.3) 
Other   11 (20.0) 
*Column greater than 100% as more than one reason could be given per person         69 
 
 
 
 
 
Table 4.2 Current management if patient considered overweight/obese 
Management  n (%)* 
Refer to hospital dietitian for your area  40 (74.4) 
Refer to clinical nurse specialist  1 (1.9) 
Refer to obesity specialist physician  0 (0.0) 
Refer back to GP for management  15 (27.8) 
Refer to commercial slimming organisation  2 (3.7) 
No action  3 (5.6) 
Other referral  9 (16.7) 
*Column greater than 100% as more than one option could be chosen  
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Chapter 5 
 
Influence of red meat consumption on iron 
status in dieting pre-menopausal women         71 
 
5.1  Introduction 
The  prevalence  of  obesity  has  risen  significantly  over  the  last  decade  and  with  it  the 
already huge numbers of women attempting to control their weight.  Young women often 
have poor iron status (NDNS 2004, vol 4, SHS 2003), and habitual dieting is reported to 
have a negative effect on iron stores (Houston et al., 1997).  In Europe and the USA, while 
diet alone is seldom the cause of iron deficiency (Frewin et al., 1997) poor dietary intake is 
not an uncommon contributory factor (Goddard et al., 2005).  Red meat is an important 
source of iron in its most bio-available form haem iron (Rossander-Hulthen., et al., 1996) 
(Table 5.1).  Although haem iron is the most bio-available non-haem iron, found in cereals, 
fruit vegetables, roots and beans, is a significant source of dietary iron (Rossander-Hulthen 
& Hallberg 1996).  Absorption of haem iron is between 15-40% of intake while absorption 
of non-haem iron is lower at 2-20% of intake (Ball et al., 1999, Hunt, 2003).  The reference 
nutrient intake (RNI) for iron in women is 14.8 mg per day (COMA).  However national 
survey data shows that in the UK women consume only around 10mg of iron per day from 
food sources and that 40% of younger women have iron intakes below the lower reference 
nutrient intake (LRNI) (NDNS 2004, vol 5). 
 
In the UK around 12% of the population are estimated to be either vegetarian or avoid 
consuming red meat (Harvey et al., 2005).  The dietary iron in vegetarian diets is less bio-
available  than  non  vegetarian  diets  because  of  reduced  meat  intake  and  an  increased 
consumption of plant based inhibitors of iron absorption (Hunt, 2003).   
This  project  was  designed  to:-determine  the  effect  on  body  weight  and  iron  status  in 
women  of  a  programme  of  weight  loss  and  maintenance,  which  includes  the  regular 
consumption of red meat in comparison to one that excludes it.  The hypothesis to be tested 
was that the inclusion of red meat in a weight reduction diet on at least 5 occasions per         72 
 
week  would  protect  iron  status  to  a  greater  extent  than  a  weight  reduction  diet  that 
excluded it.   
 
The study was devised to address the following research questions: 
RQ6  Does a weight reduction diet, that regularly includes lean red meat, maintain iron 
status in pre-menopausal women? 
RQ7  Does a weight reduction diet, which excludes lean red meat, maintain iron status in 
pre-menopausal women? 
RQ8  Does the effects on iron status differ between treatments? 
 
5.2 Methods 
The study design, setting and data analysis have been described in Chapter 2 (Methods). 
 
5.3 Results 
5.3.1 Recruitment  
Recruitment commenced in April 2005.  Within the first month it was evident that the 
response  to  the  study  advertisement  was  poor  and  that  the  ferritin  exclusion  criteria 
initially set by the Research Ethics Committee made eligibility difficult.  Application was 
made to the Ethics committee on 26
th April 2005 to extend the upper level for serum 
ferritin to 20ug/l and this was approved.   
 
It was also felt that potential volunteers were reluctant to approach the study researcher in 
person in front of colleagues within their worksite.  A mobile telephone was purchased and 
recruitment posters amended to include the telephone number.  This allowed volunteers to 
contact the researcher privately to discuss participation.  Application was also made to the 
ethic’s committee to extend recruitment to other worksites.  Further worksites were then         73 
 
identified  and  recruited  via  the  Scotland’s  Health  at  Work  initiative 
(www.healthyworkinglives.com).  Recruitment continued until the end of May 2006.   
 
One hundred and sixty women, from 12 separate worksites, volunteered to participate in 
the study.  The mean age of volunteers was 42 (SD 7.4) years and mean BMI was 31.9 (SD 
4.8)  kg/m
2.    In  three  cases  it  was  not  possible to  obtain  a  blood  sample  to  determine 
baseline serum ferritin or haemoglobin.  Fifty eight percent of volunteers (n=93) had a 
serum ferritin level greater than 20 and were therefore ineligible to participate.  In 26 cases 
(16%)  the  serum  ferritin  levels  were  below  the  10ug/l  level,  imposed  by  the  ethics 
committee, and were therefore excluded.  All of these women were informed that their 
ferritin  levels  were  low  and  advised  to  visit  their  general  practitioner  to  discuss  their 
results.  Blood results were forwarded to each general practitioner.   
 
Thirty-eight women (23.7%) fulfilled the inclusion criteria and were eligible to participate.  
Following  baseline  screening  one  woman  decided  not  to  participate  and  another  was 
started on iron supplements by her general practitioner.  In total 36 women entered the 
randomised controlled study.   
 
5.3.2 Attrition 
Six subjects (4 meat group, 2 no meat) withdrew their participation, 5 during the initial 12-
week weight loss period and one during the weight maintenance period.   The reasons 
given for withdrawal were:– unable to continue excluding red meat, not willing to include 
red meat in line with study protocol, not following eating plan, too many things going on in 
their personal life.  In two cases it was not possible to elicit the reason for withdrawing as 
both women failed to respond to any form of contact.   
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5.3.3 Study Power 
Original sample size calculations indicated that a study based on 25 analysable patients per 
group (i.e. 33 recruited per group allowing for 30% dropouts) would have power of 80% to 
detect as statistically significant a difference between the baseline to week 24 changes in 
the  two  study  groups  of  6.8  units  in  serum  ferritin  and  would  represent  a  clinically 
meaningful  improvement.    In  the  current  study,  despite  14  months  recruitment  and 
considerable extra commitment of time and unfunded resources, this was not achieved.   
The achieved sample of 30 subjects provided 80% power to detect or exclude a difference 
in the mean changes in serum ferritin between the meat and no meat groups of 8.3 units, 
rather than 6.8 units.  Alternatively, 30 subjects gave 63% power to detect the difference of 
6.8 units specified in the original protocol. 
 
5.3.4 Baseline Measurements 
The 36 subjects were randomised to 2 groups, 19 to the meat group and 17 to the no-meat 
group.    Following  randomisation  the  physical  characteristics  of  the  two  groups  were 
similar (Table 5.2).  Serum ferritin levels were <15ug/l in 11 women (30%), one woman 
had  a  haemoglobin  level  <12g/dl.    A  significant  difference  in  baseline  serum  ferritin 
observed between the meat and no meat groups respectively 17.0 (SD 2.3) vs. 14.5 (SD 
3.5) ug/l p=0.02.   
Fifteen women (41.6%) described their menstrual bleeding as either heavy or very heavy. 
 
5.3.5 Baseline Dietary Habits 
The dietary habits of the two diet groups were broadly similar at baseline.  Around 50% of 
both groups consumed fruit less than once a day with around one third of each group eating 
fruit  only  2  to  4  times  per  week  (Fig  5.1).    More  participants  in  the  no-meat  group         75 
 
consumed vegetables daily at baseline in comparison to the meat group (Fig 5.3 & 5.4).  In 
both groups the majority of participants consumed red meat 2 to 4 times per week (Fig 
5.6).  A similar picture was seen for consumption of poultry (Fig 5.7).  Around 30-40% of 
both groups consumed white fish at least once a week, however 40% of those in the meat 
group did not eat white fish at all (Fig 5.8).  The majority of those in the no meat group did 
not  eat  oily  fish  at  all  compared  to  only  one-third  of  the  meat  group  (Fig  5.9).  
Consumption  of  potatoes,  rice  or  pasta  was  low  in  both  groups  with  only  30-40%  of 
participants in each group eating these carbohydrate rich foods once a day (Fig 5.11).  In 
both groups high fat and sugary foods were eaten regularly (Figs 5.12 -5.16).  White bread 
was the bread of choice in almost half of participants in both groups at baseline (Table 
5.7).   
 
5.3.6 Energy Prescription 
Daily  energy  prescriptions  ranged  from  1200  to  1700  kcal/day.    Thirty  percent  of 
participants were prescribed 1300 kcal per day. 
 
5.3.7 Serum Ferritin  
An increase in serum ferritin between baseline and week 24 was observed in both diet 
groups.  When the data were examined for the groups combined this rise was significant, 
+3.24 (SD 9.02) ug/l p=0.03.  However within group increases did not reach statistical 
significance (Table 5.3).  Although the mean increase in serum ferritin was greater in the 
meat consumers, between-group analysis showed no significant differences in the changes 
in serum ferritin (Table 5.3).  Similarly no between group difference was evident in mean 
serum ferritin concentrations at week 24 (Table 5.4).   
         76 
 
However  while  iron  status  did  not  deteriorate  as  people  lost  weight  there  is  some 
suggestion (p =0.07), that in patients allocated to the meat diet, better adherence to dietary 
advice, with greater weight loss, led to greater improvements in serum ferritin (Fig 5.17).  
The  inclusion  of  red  meat  provides  greater  dietary  variety  and  may  have  facilitated 
improved adherence with dietary advice. 
 
5.3.8 Weight Change (0-12 weeks) 
Analysis showed a reduction in mean weight from 78.4 (SD 11.1) kg at baseline to 75.6 
(SD 11.8) kg at week 12, p<0.0001.  Within group reductions in weight were significant, 
2.8 (SD1.9) kg, p<0.0001 in the meat group, and 2.6 (SD 2.4) kg, p<0.0001.  Comparative 
analysis showed no difference in weight loss between those who included meat in their diet 
and those who excluded it p=0.69.   
Reductions in weight were mirrored by reductions in waist circumference in both the meat 
and  no  meat  groups  respectively  –3.2  (SD  3.4)  cm  p=0.001  and  –3.5  (SD  3.0)  cm 
p<0.0001.  No between significant group differences were seen in mean waist reduction. 
Of those who completed the weight loss period (n=31) all, except one, lost weight.  Mean 
percentage weight loss was 4.2 (SD 2.7) %, p<0.000.  Of the 30 women who lost weight 
20 (67%) lost 0- 5% of initial body weight.  Ten women (33%) achieved between 5 and 
10% weight loss.  Comparison between the meat and no meat group respectively showed 
no difference in terms of percentage weight loss 4.5 (2.2) vs. 3.8 (3.2)% p=0.50. 
 
5.3.9 Weight Maintenance (12-24 weeks) 
Thirty subjects completed the full 24-week programme.  Mean weight gain in those who 
completed the programme was +0.22 (SD 1.3) kg, p =0.37 with no significant between 
group differences seen, meat +0.28 (SD 1.4) kg, no meat +0.17 (SD 1.3) kg, p=0.83.           77 
 
 
5.3.10 Dietary Habits 
Weight loss period (0-12weeks) 
Significant  improvements  were  seen  in  the  dietary  habits  of  subjects.    Over  90%  of 
subjects in both diet groups increased their intake of fruit and vegetables during the weight 
loss period.  In both groups the majority of participants consumed > 5 portions of fruit and 
vegetables per day.  
Similarly the majority of subjects in both groups increased their consumption of potatoes, 
rice, pasta and breakfast cereal.  Two thirds of both groups consumed breakfast cereal 
every day of the week, and the majority of both groups ate potatoes, rice or pasta daily (75-
93%).  
 
No  between  group  differences  were  seen  in  the  proportion  of  participants  changing 
favourably their intake of these food groups during the weight loss period (Table 5.5).  
Frequency of bread consumption remained largely unchanged, however at week 12 the 
majority of subjects in each group consumed brown, granary or wholemeal bread instead 
of white bread (Table 5.7).   
 
Between  group  differences  were  seen  in  the  proportion  of  subjects  increasing  their 
consumption of both white and oil rich fish.  More subjects in the no-meat group increased 
their consumption of these foods (Table 5.5).  At week 12, 46% of those in the no meat 
group  were  consuming  white  fish  between  2  and  7  times  per  week.    A  significant 
proportion  of  subjects  in  the  no  meat  group  increased  their  consumption  of  poultry 
however no significant between group difference was observed.           78 
 
A significant number of subjects in the meat group increased their consumption of red 
meat during the weight loss period (p=0.003, sign test) from 3 times per week at baseline 
to 5-7 times per week.   
  
A significant proportion of subjects in both groups reduced their frequency of consuming 
sweets, chocolates and savoury snacks (Table 5.5).  The proportion eating sweets on a 
daily basis fell to 21% from 37% in the meat group and from 29.5 to 6% in the no meat 
group.  
 
Weight Maintenance period (12-24 weeks) 
Overall  the  improvements  in  diet  observed  at  the  end  of  the  weight  loss  period  were 
maintained throughout the weight maintenance period.  However, a significant proportion 
of subjects in the meat group decreased their consumption of fruit and vegetables (Table 
5.6), 40% of women ate fewer than 5 portions per day. 
 
Dietary  assessment  in  the  present  study  was  performed  using  a  food  frequency 
questionnaire and not weighed intake diaries.  A limitation of the study is that it was not 
possible to make accurate calculations of dietary iron intake.  However taking a 1300 kcal 
eating plan as an example (Appendix 6), it was we estimated that potential availability of 
dietary  iron  was  approximately  28.6  and  27.6mg/d  for  the  meat  and  no-meat  group 
respectively, with the majority being non-haem iron.  These figures could vary widely 
depending on individual food choice, the consumption of inhibitors and enhancers of iron 
absorption and compliance with portion advice.  
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5.4  Discussion 
A  widespread  belief  that  red  meat  is  “high  in  fat”  means  that  for  many,  self  directed 
attempts  at  “dieting”  are  characterised  by  the  exclusion  of  red  meat  from  their  diets 
(Houston et al., 1997).  However red meat is an important source of iron in its most bio-
available form (Rossander-Hulthen & Hallberg 1996) and its exclusion from the diet may 
be a contributory factor in the prevalence of iron deficiency, especially in young women.  
Previous research has shown that “reducing fat and cholesterol intake” are frequently cited 
as reasons for not eating red meat (Houston et al., 1997).  The Scottish Diet Report (1993) 
stresses that while consumption of “meat products” needs to be reduced because of their 
very high saturated fat content, consumption of red meat itself need not be reduced on 
nutritional  grounds.    Previous  research  has  shown  that  in  terms  of  weight  loss  and 
improvements in plasma lipids the elimination of red meat from the diet is unnecessary 
(Leslie et al., 2002, Watts et al., 1988). 
 
The prevalence of iron deficiency in the present study was greater than reported for the 
female Scottish population, with 16% of volunteers ineligible to participate because of iron 
deficiency.  These data indicate that iron deficiency is under-recognised and untreated in 
the Scottish female population.   
 
The number of volunteers within each worksite was low.  This was in contrast to previous 
dietary/weight management studies carried out by this department in a worksite setting, 
which have attracted a large number of volunteers (Leslie et al., 2002).   A recent review of 
worksite interventions reports that program/initiatives that rely on individual motivation 
alone  are  likely  to  be  less  successful  than  programs  that  also  include  environmental 
strategies (Goetzel 2008).  While the worksites/employers that participated in the present 
study were supportive they were not actively involved in promoting the initiative and no         80 
 
additional environmental interventions were run by the worksites in parallel to the present 
study.  This may have contributed to our low volunteer rate as employees may perhaps felt 
their employers were not wholly supportive of their participation in the study.   
 
The low recruitment rate combined with the higher prevalence of iron deficiency in our 
volunteers were significant factors in the non-achievement of the intended study numbers.  
The women excluded because of low ferritin were not symptomatic, but there was concern 
from the Ethics Committee that dietary intervention could provoke anaemia.  The results of 
this study suggest that both diets actually improved iron status, so excluding subjects with 
ferritin <10ug/l was unfortunate. 
 
Attrition from weight management studies can be high (Honas et al., 2003, Rossner, 1992), 
and was anticipated to be around 30% in the present study.  However the attrition rate was 
low at just under 17%.  Low attrition is thought to be an indicator of some success and it is 
suggested that programs with low attrition rates will be successful (Rossner, 1992).  The 
low attrition rate in the present study suggests that compliance with the eating plans was 
not difficult for participants.  Compliance is a key issue in weight management and may 
not  only  optimize  weight  loss,  but  lead  to  long-term  changes  in  dietary  habits,  thus 
improving the likelihood of maintaining weight loss and improving long term health.   
Given  the  low  attrition  rate  found  in  the  present  study,  had  the  prevalence  of  iron 
deficiency  in  our  population  sample  been  lower,  the  required  study  numbers  could 
potentially have been achieved. 
At baseline just under one-third of participants in the present study fulfilled the criteria for 
iron depletion and were therefore at higher risk of iron deficiency.  A significant between 
group difference in serum ferritin was observed at baseline, however as participants had         81 
 
been randomly allocated to the treatment groups this difference can only be attributed to 
chance (Burgess et al., 2003). 
 
Pre-menopausal women are susceptible to iron deficiency anaemia due to the demands of 
pregnancy and menstruation on their smaller iron stores.  Previous research has found that 
ferritin status is inversely related to menstrual blood loss – higher blood loss leading to 
lower  ferritin  levels  (Harvey  et  al.,  2005).    In  the  present  study  just  over  40%  of 
participants  described  their  monthly  blood  loss  as  either  heavy  or  very  heavy,  again 
increasing their risk of developing iron deficiency anaemia. 
 
Improvements in serum ferritin, from baseline to week 24, were observed in both diet 
groups over the study period.  Haem iron is the most bio-available of the two forms of 
dietary iron with 20-25% absorbable compared with 1-5% of non-haem (Hercberg et al., 
2001).    Red  meat  is  a  rich  source  of  haem  iron  and  its  presence  also  enhances  the 
absorption of non-haem iron (Cook, 1976).  Other protein sources such as poultry, white 
and oil rich fish are also important sources of haem iron (McCance & Widdowson 2002)
 
(Table 12) and the capacity to enhance the absorption of non-haem iron is also found, 
although  to  a  lesser  extent,  with  these  foods  (Cook,  1976)  .    In  the  present  study 
consumption of haem iron was increased in both diet groups. 
 
Non-haem iron, found in cereals and fruit vegetables is also a significant source of dietary 
iron
 (Gregory et al., 1990).  Since the late eighties however the contribution from meat, 
meat products, fish and poultry to iron intake has decreased to around 16% from 21% 
(MAFF  2000).    It  is  therefore  non-haem  iron  that  provides  the  bulk  of  dietary  iron 
(Gregory et al., 1990).  The dietary advice given in the current study was designed to 
provide around 50% of total energy from carbohydrate, much of which was provided by         82 
 
bread and cereal products.  Consumption of these foods was increased in both diet groups.  
The consumption of fruit and vegetables also increased in the study population and it can 
be assumed that a variety of fruits were eaten including those rich in ascorbic acid, which 
is  known  to  enhance  the  absorption  of  non-haem  iron  (Rossander-Hulther  &  Hallberg 
1996, Monsen 1988) .   
 
The improvement in ferritin concentrations, seen in both diet groups, reflects both groups 
consuming  a  healthier  balanced  diet  that  was  richer  in  both  haem  and  non-haem  iron.  
However, the rise in ferritin in both groups may also, in part, reflect regression to the mean 
(RTM), as subjects were recruited on the basis of low ferritin.  Approaches to reduce this 
effect include random allocation to comparison groups (Barnett et al., 2005).  Random 
allocation ensures that RTM effects should be the same in all groups.  The inclusion of a 
placebo group allows an estimate of the RTM effect.  In the present study participants were 
randomly allocated to one of two dietary groups, however this study did not include a 
placebo  group.  Another approach to minimise RTM is the use analysis of covariance 
(ANCOVA)  (Barnett  et  al.,  2005).    This  adjusts  participants  follow  up  measurements 
according to their baseline value.   In the present study changes in serum ferritin were 
analysed using ANCOVA.  The use of both these approaches may have lessened the RTM 
effect. 
 
The available data do suggest that the meat diet may be better.  Although differences in 
serum  ferritin  were  not  significant  at  week  24,  during  the  weight  maintenance  period, 
(week 12 to 24), ferritin continued to rise in the meat group while, in contrast, tended to 
fall  in  the  no  meat  group.    Whilst  improvements  in  dietary  habits  were  in  general 
maintained during this period, in both groups the majority of subjects reduced their intake 
of fruit and vegetables therefore lowering their intake of Vitamin C, a known enhancer of         83 
 
non-haem iron.  The continued rise in serum ferritin levels in the meat consumers suggests 
a benefit from regular meat consumption in that it compensated for the fall in fruit and 
vegetable consumption, and the fall in serum ferritin observed in the no meat group was 
prevented.  Additionally the 95% confidence intervals for the change in ferritin at week 24 
were wide, and this does not allow us to exclude the possibility of a moderately large 
difference in favour of the meat diet.   
 
However  as  the  present  study  was  underpowered  it  is  not  possible  to  draw  definitive 
conclusions from these data.  Previous research has reported a positive correlation between 
red meat consumption and serum ferritin levels, and proposed that this was due to the 
increased availability of haem iron (Cade et al., 2005).  Other research has found that 
women eating a diet rich in haem iron were found to have the highest serum ferritin levels, 
and red meat is the richest source of haem iron (Leggett et al., 1990).  It is also important 
to note that the eating plans used in the present study were designed to optimise nutrient 
intakes,  including  iron,  and  iron  status  may  have  been  preserved  because  of  a 
compensatory increase in the consumption of other dietary sources of iron.  The eating 
plans were therefore likely to be nutritionally superior to those of self-directed slimmers.  
The  elimination  of  red  meat  as  part  of  slimming  plans  without  concomitant  dietary 
improvements may well deplete iron stores and contribute to iron deficiency and anaemia.  
The achieved weight loss was similar in both groups and there would appear to be no 
differences in acceptability or compliance.  The healthiest way to achieve weight loss is by 
following a balanced diet in which no food group is restricted or eliminated (NICE 2006).   
Anecdotally many of the women in the no meat group reported that they were looking 
forward  to  including  meat  in  their  diet  once  the  study  period  was  over.    Its  inclusion 
provides a more varied diet, a good source of iron and is part of a healthy balanced diet on 
which any weight reducing diet should be based.         84 
 
 
The failure of any weight management programme is more often than not a failure of 
maintenance rather than failing to achieve some weight loss (Wadden et al., 1989).  In the 
present study no significant weight regain was observed amongst the participants in either 
diet group.  Continued “therapist contact” is consistently reported as a factor in improving 
weight maintenance (Perri et al., 1993).  The weight maintenance data in the present study 
are likely to reflect the continued one to one contact.  The apparent acceptability of the 
eating plans is also a likely contributory factor in the maintenance of achieved weight loss.  
  
Worksites  provide  a  promising  location  for  future  weight  management  interventions.  
Health promotion or occupational health personnel are in a position to target obesity and 
weight management and contribute to reducing the prevalence of obesity and associated 
disorders. However in order to maximise uptake and success they should be initiated and 
promoted by management, with input from employees, and supported by environmental 
interventions (Goetzel et al 2008). 
 
5.5  Conclusion  
The  presence  of  iron  deficiency  amongst  our  volunteers  was  higher  than  expected  or 
reported by previous research and many of the women who were eligible to participate 
were iron depleted and therefore at increased risk of iron deficiency.  These data are likely 
to reflect the poor dietary habits of our participants and the population in general.  The 
present study provided answers to the research questions: 
 RQ6  Doe a weight reduction diet, that regularly includes lean red meat, maintain iron 
status in pre-menopausal women? 
RQ7  Does a weight reduction diet, which excludes lean red meat, maintain iron status in         85 
 
pre-menopausal women? 
RQ8  Does the effects on iron status differ between treatments? 
Excluding red meat did not adversely affect iron status, and iron status improved in both 
groups over the study period.  The eating plans used were designed to optimise nutrient 
intakes,  including  iron,  and  iron  status  may  have  been  preserved  because  of  a 
compensatory increase in the consumption of other dietary sources of iron.  However the 
data,  although  not  definitive,  do  suggest  improvements  in  iron  status  from  prolonged 
regular consumption of red meat (RQ 8).  A larger study over a longer time frame would 
be  required  to  produce  data  to  support  definitive  advice  for  health  promotion.    The 
inclusion of red meat provides a more varied diet and remains a rich source of dietary iron, 
which should be included as an option in any healthy balanced diet for weight loss or 
stability.         86 
 
 
Table 5.1 Iron content of commonly consumed sources of animal protein 
 
Source  
(cooked) 
*Fe  
(mg per 100g) 
% Haem Iron 
(cooked) 
Beef  1.4-3.6  78** 
Lamb  0.7-2.6  70**  
Pork  0.4-1.1  52** 
Poultry  0.4-2.7  28** 
White fish  0.1-1.2  20-40*** 
Oil rich fish  0.4-5.1  20-40#(uncooked) 
 
Data from:- 
*FSA (2002)McCance and Widdowson, The Composition of foods (6
th Summary 
Edition): ** Lomabardi-Boccacia et al 2002: ***Rangan et al 1997: # Gomez-
Basuauri & Regenstein 1992. 
 
 
Table 5.2 Baseline measurements for participants randomised to the meat and no 
meat diet groups. 
  Meat 
(n=19) 
No Meat 
(n=17) 
p 
Age  41 (7.9)  41 (7.2)  0.88 
BMI  29.9 (4.4)  30.1 (3.6)  0.89 
Weight (kg)  78.8 (12.9)  78.0 (9.1)  0.84 
Waist (cms)  98.2 (11.3)  94.9 (8.4.)  0.32 
Serum Ferritin (ug/l)  17.0 (2.3)  14.6 (3.5)  0.02 
All data expressed as mean and (SD)  
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Table 5.3  Mean (SD) for change in serum ferritin from baseline to week 24 
Diet   Change in serum ferritin 
ug/l  
S.E   95% CI  p 
Meat  + 4.42 (10.7)  2.45  -0.74 to +9.56  0.08 
No meat  + 1.93 (6.7)  1.63  -1.54 to +5.41  0.11 
Between  group 
difference 
2.48   3.02  -3.66 to +8.63  0.41 
 
 
 
Table 5.4 Mean serum ferritin (SD) at week 24 by diet group and between group difference 
in serum ferritin at week 24 by ANCOVA adjusting for baseline differences. 
 
Diet   Serum ferritin at week 24 
ug/l 
S.E   95% CI  p 
Meat  21.42 (11.63)  2.67     
No meat  16.52 (7.84)  1.90     
Between  group 
difference 
+1.16  3.27  -5.49 to +7.83  0.72 
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Table  5.5    Number  of  subjects  increasing/decreasing  intakes  of  food  groups  during  the 
weight  loss  period,  and  comparison  of  the  proportion  of  subjects  increasing/decreasing 
intakes by diet group 
Weight Loss Period  (0-12 weeks) 
  Decreasing  Same  Increasing  p  
(sign 
test) 
Meat v no 
meat 
(Odds ratio) 
95% CI  p 
Potatoes, rice, pasta               
Meat  1  7  8  0.04  0.66  0.16 to 2.76  0.57 
No meat  2  4  9  0.06       
Breakfast cereal               
Meat  1  7  8  0.04  1.1  0.27 to 4.68  0.85 
No meat  2  6  7  0.18       
Fruit & vegetables               
Meat   1  0  15  0.001  1.0  0.06 to 18.8  0.96 
No meat  1  0  14  0.001       
Oily fish               
Meat   4  9  3  1.0  0.13  0.26 to 0.72  0.02 
No meat  0  5  10  0.002       
White fish 
             
Meat  5  9  2  0.45  0.52  0.008 to 
0.33 
0.002 
No meat  2  2  11  0.02       
Poultry 
             
Meat  2  9  5  0.45  0.39  0.92 to 1.72  0.21 
No meat  0  7  8  0.008       
Savoury snacks 
             
Meat   13  2  1  0.002  1.5  0.28 to 8.61  0.60 
No meat  11  4  0  0.001       
Sweets/chocolates 
             
Meat   12  2  2  0.01  0.75  0.13 to 4.09  0.74 
No meat  12  2  1  0.003       
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Table 5.6 Number of subjects increasing/decreasing intakes of food groups during the weight 
maintenance period and comparison of proportion increasing/decreasing intakes by diet group 
  
  Decreasing  Same  Increasing  p 
(sign 
test) 
Meat v no 
meat 
 
95% CI  p 
Potatoes, rice, pasta               
Meat  2  11  1  1.0  1.0  0.12 to 8.21  1.0 
No meat  2  11  2  1.0       
Breakfast cereal               
Meat  4  9  2  0.68  0.66  0.94 to 4.73  0.68 
No meat  1  11  3  0.62       
Fruit & vegetables               
Meat   12  0  3  0.03  0.50  0.09 to 2.6  0.41 
No meat  9  1  5  0.42       
Oily fish               
Meat   2  10  3  1.0  0.68  0.12 to 3.82  0.66 
No meat  5  5  4  1.0       
White fish 
             
Meat  2  8  5  0.45  2.2  0.41 to 11.8  0.34 
No meat  6  6  3  0.50       
Poultry 
             
Meat  2  12  1  1.00  1.00  0.57 to 176  1.00 
No meat  5  9  1  0.21       
Savoury snacks 
             
Meat   3  8  4  1.00  1.6  0.23 to 11.46  0.62 
No meat  1  9  4  0.68       
Sweets/chocolates 
             
Meat   4  8  3  1.00  0.42  0.15 to 3.49  0.69 
No meat  3  9  3  1.00               90 
 
 
Table 5.7 Type of bread eaten at baseline and week 12 in both diet groups 
 
  White  Brown, granary 
Wheatmeal 
Wholemeal  Mixture  No usual type 
  Baseline 
 
Wk 12  Baseline  Wk 12  Baseline  Wk 12  Baseline  Wk 12  Baseline  Wk 12 
Meat group 
(n=19) 
 
9 (47.4)  1(5.3)  7(36.8)  9(47.4)  1(5.3)  6(31.6)  2(10.5)  0  0  0 
No meat 
group (n=17) 
 
7(41.2)  1(5.9  4(23.5)  5(29.4)  2(11.8)  8(47.1)  1(5.9)  1(5.9)  3(17.6)  0 
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Figure 5.17 Relationship between weight change and changes in serum ferritin by diet 
group 
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Chapter 6 
General Discussion   97 
6.1 Introduction 
The health of the Western world is changing and many countries face a rising toll of death 
and disability from chronic non-communicable diseases.  Many of the risk factors for these 
diseases  are  diet  related  and  there  are  clear  links  with  obesity.  The  development  of 
strategies for the treatment and prevention of obesity is a priority for health promotion and 
education, and weight management guidelines have been produced by both government 
and  professional  bodies.    However  the  management  of  obesity  remains  ad-hoc  and 
fragmented with no concerted strategy in place in the UK or many other countries.  The 
recent Foresight report (2007) stresses that all factors that contribute to the rising tide of 
obesity  require  to  be  recognised  and  addressed,  and  highlights  the  need  for  long  term 
approaches utilising a wide range of interventions.  
 
This thesis has investigated three factors associated with either the aetiology of, or the 
management/treatment of obesity: 
 
1  the  effect  that  some  commonly  prescribed  drugs,  used  in  the  treatment  of 
chronic  non-communicable  diseases  associated  with  obesity,  can  have  as  an 
adverse effect on body weight,  
2  current  practice  in  secondary  care  clinics,  where  the  management  of  non-
communicable  diseases  associated  with  obesity  and  treated  with  drugs 
associated with weight gain is set, with regard to the identification and initiation 
of treatment for patients who are overweight or obese, and  
3  which  dietary  approach  for  weight  loss  and  weight  loss  maintenance  would 
preserve iron status in pre-menopausal women, a group at increased risk of iron 
deficiency, who are identified as overweight or obese. 
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6.2. Research Questions and Answers 
 
RQ1  Is weight gain an adverse effect of some commonly prescribed drugs?   
RQ2  Is the effect on body weight reported and quantified in studies examining these 
drugs? 
The  research  carried  out  as  part  of  this  thesis  has  provided  evidence  that  drugs  can 
contribute to weight gain especially those used to treat psychiatric disorders.  Not all drugs 
associated with weight gain were included, however those that were are those consistently 
reported  in  medical/scientific  literature  and  used  to  treat  chronic  non-communicable 
diseases. 
About 15 million people are on beta-blockers often for conditions made worse by weight 
gain.  Weight gain is clearly an important side effect whose importance is much greater in 
the 21
st century that in the 1960’s when beta-blockers were first introduced.   
Similarly,  most  schizophrenic  patients  receive  antipsychotic  drugs.    Prescribing  has 
increased since the NICE recommendation of atypical antipsychotics as a first line option 
in the treatment of schizophrenia.  In 2006-07 prescriptions accounted for two-thirds of all 
antipsychotic prescriptions.  Half these patients could therefore expect a weight gain of 
between 3 and 10 kg.  The potential for any side effect, including weight gain, should be 
discussed with patients at the commencement of treatment using any drug that is associated 
with weight gain.  The use of alternative drugs may be possible and should be considered.  
However  if  this  is  not  possible  then  all  support  should  be  available  to  help  patients 
minimise the potential weight gain and related non-communicable diseases associated with 
obesity.  The numbers in the population receiving treatment with drugs associated with 
weight  gain  has  risen  significantly  and  may  rise  further.    Thus  pharmacotherapy  has 
become a significant factor in the continuing rising prevalence of obesity.  Schizophrenia is 
now recognised as a high risk condition for obesity, type 2 diabetes and coronary heart 
disease (Lean & Pajonk 2003).     99 
As our environment has grown increasingly obesogenic and more people are given more 
drugs it is now important to make good data on obesogenicity as a side effect and on 
effective means to combat it.  Obesogenic drugs are used by GP’s and also by secondary 
care specialists.  All should take responsibility for managing this side effect within their 
practice.   
 
RQ3 Are formal protocols to routinely identify and manage overweight/obese patients in 
place in secondary care clinics? 
RQ4   Is height and weight routinely measured in secondary care clinics? 
RQ5  What steps are taken to manage patients who are identified as overweight or obese? 
This thesis has also highlighted that little is being done in secondary care settings, where 
the treatment of many disorders associated with obesity is coordinated, to identify and 
initiate  treatment  for  those  who  are  overweight  or  obese.    The  findings  concur  with 
previous research (Cleator et al., 2002) and suggest that little has changed since this earlier 
research. 
 Although  there  was  a  willingness  amongst  some  clinicians  to  contribute  to  the 
identification and management of obesity greater training and resources are required to 
facilitate this.  In the majority of cases patients who were identified as overweight or obese 
were referred to a dietitian or back to their own GP.  In many clinics height and weight 
were not routinely measured thus the opportunity to identify those who were overweight or 
obese was missed.  Effective tackling of the current “obesity epidemic” will require the 
involvement of all sectors of the NHS and there should be an integrated approach between 
primary and secondary care.   
 
A  recent  Medline  literature  search  found  only  one  publication  reporting  on  the 
management  of  overweight  patients  in  a  clinic  setting  (Osland  et  al.,  2007).    Weight 
management was promoted as an important aspect of care for patients attending a liver   100 
management clinic and researchers’ reported that providing an intervention for overweight 
patients  in  a  clinical  outpatient  setting  was  a  feasible  treatment  option  for  weight 
management. 
The results of this survey suggest that weight management should be an integral part of the 
management  and  treatment  of  all  chronic  non-communicable  diseases  as  it  can  impact 
positively on treatment and outcomes. 
 
RQ6  Does a weight reduction diet, that regularly includes lean red meat, maintain iron 
status in pre-menopausal women? 
RQ7  Does a weight reduction diet, which excludes lean red meat, maintain iron status in 
pre-menopausal women? 
RQ8  Does the effects on iron status differ between treatments? 
The final study carried out as part of this thesis has shown that improvements in iron status 
can be achieved during weight loss using eating plans that either include or exclude red 
meat.   
The data however do suggest that a diet including red meat may confer greater benefits on 
iron  status,  however  as  the  study  was  underpowered  definitive  conclusions  are  not 
possible.  Earlier research has shown that a meat rich diet was better than supplementation 
at preserving iron status in premenopausal women participating in an exercise programme 
(Lye et al., 1992).  Other research that compared the effect of iron supplementation and an 
iron rich diet, showed that while the improvements in serum ferritin achieved with diet 
were smaller than with supplementation, serum ferritin continued to improve in the diet 
group beyond the intervention period (Patterson et al., 2001).   
The inclusion of red meat provides a more varied diet, a good source of iron and can be 
part  of  a  healthy  balanced  diet  on  which  any  weight  reducing  diet  should  be  based.  
Compliance  is  a  key  issue  in  weight  management.    Attrition  and  weight  regain  in  the 
present  study  were  low  and  the  provision  of  a  varied  diet  is  likely  to  have  been  a   101 
contributory factor.  It is important that any dietary approach for weight loss facilitates 
weight loss in a way that does not contribute to the development of nutritional deficiencies. 
However  a  larger  study  over  a  longer  period  is  required  to  provide  data  to  support 
definitive advice. 
 
6.3 Future Research Topics 
The possible future research generated by this thesis: 
·  Can effective interventions be developed to address weight gain in patients who are 
prescribed drugs associated with weight gain, in both primary and secondary care? 
·  What resources and training do secondary care clinic staff require to identify those 
who are overweight or obese, and then initiate treatment within medical specialties?   
·  What advice and treatment are pre-menopausal women who are identified as iron 
deficient or with iron deficiency anaemia routinely given? 
·  Do  all  weight  loss  programmes  (commercial,  self  help)  advocate  a  healthy 
nutritionally balance diet? 
 
6.4 Research Skills developed within this thesis 
•  Questionnaire development 
•  Critical appraisal of research literature 
•  Systematic review methodology 
•  Critique of evaluation tools 
•  Co-writing of grant applications 
•  Completion of ethics applications and attendance at ethics committee meeting 
•  Redesigning intervention materials 
•  Intervention implementation and study management 
•  Preparation of manuscripts and submission for publication 
•  Preparation and delivery of presentations at International conferences   102 
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Appendix 1     Obesity/weight management audit 
 
 
Specialist Area………………………… 
 
 
 
1)  Is there a formal protocol in place within  your specialist area  for overweight/obese 
patients to receive management? 
Yes     (If yes please go to question 3)  
If you have documentation of your obesity/weight management protocol please enclose a 
copy with your completed questionnaire.  Thank you 
 
No  (If no please continue) 
 
2)  If  at  present  no  protocol  is  in  place  within  your  specialty  to  address 
overweight/obesity management can you indicate the possible reasons for this. 
Obesity/weight management not a priority for health care in general       
 
Obesity/weight management not important to this specialist area   
Expertise not available to treat obesity/overweight within this specialist area   
Personnel skilled in weight management inaccessible     
Weight management best undertaken by dedicated secondary care specialist service     
Weight management should be undertaken by a GP specialist service   
 
Other     (please specify) 
 
    
 
3a) Are patients’ height and weight routinely measured on attendance at your clinic? 
Yes            No    
 
3b) If yes who takes these measurements 
Doctor    Nurse    Nursing assistant/auxiliary    
 
4) If you consider a patient to be overweight/obese how do you manage this  
a) Referral to hospital dietitian for your area   
Do they follow the patient up     Yes       No   
b) Referral to clinical nurse specialist for your area    
Do they follow the patient up   Yes     No   
c) Referral to obesity specialist physician     
d) Referral back to GP for weight management   
e) Referral to commercial slimming organisation   
f) No action   
g) Other referral    Please specify who/where 
 
 
5) Within your specialist area do you currently give advice for reasons other than 
obesity 
Yes    (if yes please tick those appropriate below)      No  
Diet        Activity       Lifestyle  
 
    
6a)  Within  your  specialist  area  does  obesity  affect  the  outcome  or  progress  of 
treatment 
Yes              No   
6b) If yes in what way? (please state) 
 
 
 
 
7) Are you comfortable about recommending treatment with anti-obesity drugs that 
have been recommended by NICE to obese patients within your specialty 
Yes       No    
If not please state your reasons 
 
 
 
8) Two possible models of care for obesity/ weight management may exist or be 
preferred for development. 
 
Model  A:  Identify  treat  and  manage  obesity  within  each  medical  sub-specialty, 
supported by trained multidisciplinary team 
Model B: Identify and refer to specialist obesity clinic  
 
Please see over for flow diagram of each model 
 
Please indicate which model you would prefer to see implemented  
Model A        Model B   
 
We would welcome any additional comments you may have on either Model or any 
other point raised in this questionnaire    
 
 
 
 
 
 
 
 
Patient attends clinic. Concerns raised 
regarding weight 
Seen by clinic nurse and assessment carried out 
and BMI measured 
BMI > 40 or > 35 with  
Co-morbid condition 
Yes 
No 
BMI <25 
BMI 25-40 (no co-
morbid conditions)  
25-35 (with co-morbid 
conditions)  
Clinic nurse 
for healthy 
Clinic nurse for weight 
management advice 
Patient Accepts 
Refer to hospital dietitian assigned to 
specialty 
Patient 
refuses 
Weight loss programme with regular 
monitoring at each clinic visit by 
dietitian assigned to specialty  
Successful outcome  
(5-10%) weight loss 
Unsuccessful outcome 
Patient discharged 
from clinic 
Consider referral to specialist 
obesity service which includes 
bariatric surgery 
Unsuccessful outcome 
Consider addition of drug therapy 
Offer weight 
management 
Patient Accepts 
Patient 
refuses 
MODEL A 
Offer weight 
management 
Primary care for ongoing 
management    
Model B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Specialist obesity dietitian will deliver programme  
 
Patient attends outpatient clinic. 
 Concerns raised regarding weight 
Seen by clinic nurse and assessment carried out 
and BMI measured 
BMI > 40 or > 35 with  
Co-morbid condition 
Primary care for ongoing 
management
Specialist Obesity management service 
BMI 25-40 (no co-morbid conditions) 
25-35 (with co-morbid conditions
BMI < 25 
No further action 
Offer weight management  Patient refuses 
Patient accepts 
3 month weight 
loss programme * 
Unsuccessful outcome 
(< 5-10% weight loss) 
Successful outcome 
 (5-10% weight loss) 
Maintenance of weight loss.  
Regular monitoring 
Prevention of further weight gain 
Consider additional drug therapy  
Consider referral for 
surgery if BMI > 40 or 
35 with  
co-morbid condition    
 
Appendix 2 
 
RECRUITMENT POSTER 
 
 
 
 
 
 
Is iron status in dieting pre-menopausal women affected by red meat consumption? 
 
Are you interested in losing weight?  We at the Department of Human Nutrition at the University of 
Glasgow are carrying out a study and would like to invite you to take part. 
 
What’s it all about? 
Women often have low iron levels and many may be overweight.  When trying to lose weight many 
women often exclude red meat from their diet as they think it is “high in fat”.  We would like to find 
out what effect a diet for weight loss that excludes red meat has on iron levels compared to one that 
includes red meat.   
 
Who can take part? 
Women, who have not reached the menopause, are overweight, would like to lose weight and have a 
low level of iron.   
 
How will I know if I can take part? 
Two things will be checked: 
1.  height and weight to find out if you are overweight. 
2.  iron levels in a sample of your blood.   
 
If your results show that you are overweight and your iron levels are low you would be able to take 
part. 
 
What next? 
If you are eligible to take part in this study, you will be asked to follow one of two diets, one that 
allows you to eat red meat or one that doesn’t.  The diet you will be asked to follow will be decided 
by chance using a computer programme.  The study will last for 24 weeks in total, for the first 12 
weeks you will be asked to lose weight and for the second 12 weeks to maintain the weight you have 
lost.    During  the  whole  24  weeks  you  will  be  asked  to  attend  an  appointment  with  the  study 
researcher  every  2  weeks.    Your  weight  will  be  measured  and  your  progress  discussed  on  each 
occasion.  All appointments will take place at your place of work. 
 
What’s in it for me? 
You will be given expert dietary advice to help you improve your diet.  Losing weight has many 
health benefits.  
 
Interested in taking part: what next? 
If you are interested in taking part you can call us on 07814 066 483 Monday to Friday between 9am 
and 5pm and we can discuss the study in more detail without any obligation on your part.  We will 
also be in……………….on……………………… Your decision on whether to take part or not, will 
not affect your employee/employer relationship in any way. 
 
Look forward to hearing from/meeting you 
 
 
Wilma Leslie            Catherine Hankey 
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Appendix 4 
Plate Models 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
The Healthy plan 13 
 
Daily allowances 
1/2 pint semi skimmed milk. (250 ml ) 
(100 ml of milk can be taken as a diet or natural yoghurt) 
 
7 x carbohydrate exchange 
2 x protein exchange 
2 x fruit exchange 
1 x wine glass fruit juice (125 ml) 
 
Low fat spread:(40g or less fat per 100g) 
20g or 2 scrapes 
 
Suggested meal plan 
 
Breakfast       
1 x glass of fresh fruit juice 
2 x carbohydrate exchange 
Spread jam or marmalade 
Tea / coffee 
 
Mid-Morning     
Tea / Coffee or low calorie drink 
 
Lunch  
2 x carbohydrate exchange 
1 x protein exchange 
Salad / vegetable 
1 x fruit exchange 
Tea / Coffee or low calorie drink 
 
Mid afternoon     
Tea / Coffee or low calorie drink 
 
Evening meal 
1 x protein exchange 
2 x carbohydrate exchange 
Salad / vegetable 
1 x fruit exchange 
 
Supper       
1 x carbohydrate exchange 
 
 
Appendix 5    
Appendix 6    Dietary Targets monitor  
(Lean  MEJ,  Anderson  AS,  Morrison  C,  Currall  J,  (2003)  Evaluation  of  a  Dietary  Targets 
Monitor. European Journal of Clinical Nutrition 57, 667-673) 
 
DATE______________        STUDY NUMBER 
 
 
1.  What kind of bread do you usually eat       
  - white   
  - brown, granary, wheatmeal   
  - wholemeal   
  - other kind (please specify)   
  - no usual type   
  - do not know   
  - do not eat bread   
 
 
2.  What do you usually spread on bread? 
  - butter   
  - hard/block margarine   
  - soft margarine   
  - reduced fat spread   
  - low fat spread   
  - no usual type   
  - do not know   
  - do not spread fat on bread   
 
 
3.  How much do you usually eat in a day? 
  less 
than 1 
1  2-3  4-5  6 or 
more 
  - slices of bread/rolls           
  - biscuits (including chocolate biscuits)           
  - cakes, scones, sweet pies and pastries           
 
 
4.  What kind of milk do you usually use for drinks in tea or coffee and on 
cereals etc? 
  - whole milk   
  - semi-skimmed   
  - skimmed   
  - other kind (please specify)   
  - no usual type   
  - do not know   
  - do not drink milk   
 
 
5.  Do you usually take sugar in: 
  YES  NO 
  (a) tea     
  (b) coffee        
  DO NOT DRINK TEA/COFFEE     
6.  At table do you: 
  YES  NO 
  - generally add salt to food without tasting first     
  - taste food and then generally add salt     
  - taste food but only occasionally add salt     
  - rarely or never add salt at table     
 
 
7.  Which type of breakfast cereal do you normally eat? 
  - high fibre (eg All Bran, Branflakes, Shredded 
    Wheat, Muesli, Porridge, Weetabix 
 
  - other (eg Cornflakes, Rice Krispies, Special K, 
    Sugar Puffs, Honey Snacks 
 
  - no usual type   
  - do not eat breakfast cereal   
 
 
8.  How often do you eat these foods 
  Per day (times)    Per week    Per month
  6+  4-5  2-3  once    5-6  2-4  once    1-
3 
Less 
than 
once 
Breakfast cereal                       
Fresh fruit                       
Cooked green vegetables 
(fresh or frozen) 
                     
Cooked root vegetables 
(fresh or frozen) 
                     
Raw vegetables or salad 
(including tomatoes) 
                     
Chips                       
Potatoes, pasta, rice                       
Meat                       
Meat products                       
Poultry                       
White fish                       
Oil rich fish                       
Cheese                       
Beans or pulses                       
Sweets, chocolates                       
Ice cream                       
Crisps, savoury snacks                       
Fruit juice (NOT squash)                       
Soft/fizzy drinks                       
Cakes, scones, sweet pies 
or pastries 
                     
biscuits                       
    
Appendix 7     1300 kcal Eating Plan 
 
 
 
Daily allowances 
 
7 x carbohydrate exchange 
2 x protein exchange 
3 x fruit exchange 
 
 
Meal 
 
Portion size  Iron Content (mg)  Vitamin C 
Content (mg) 
Breakfast       
One slice wholemeal toast  31g  0.9   
Special K  84g  19.5   
Fresh Orange juice  125ml  0.5  48.7 
       
Lunch       
2 slices wholemeal bread  52g  1.2   
Chicken breast  75g  0.5   
Banana  80g  0.2  8.8 
       
Evening Meal       
Boiled potatoes  240g  0.9  13.0 
Stewed mince OR  75g  2.0   
Fried haddock in breadcrumbs  125g  1.0   
 
Broccoli (boiled) 
 
80g 
 
1.7 
 
35.2 
Carrots (boiled)  80g  0.3  1.6 
Apple  80g  0.08  4.8 
       
Supper       
One slice wholemeal toast  31g  0.9   
       
Total    28.6 (meat) 
 
27.6 (no meat) 
 
112.1 
* Iron and Vit C content calculated using Food Composition Tables, McCance & 
Widdowson 6
th Summary Edition 2008 
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